UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2024

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM __________ TO __________

 

COMMISSION FILE NUMBER: 000-54437

 

SUNHYDROGEN, INC.

(Name of registrant in its charter)

 

Nevada   26-4298300

(State or other jurisdiction of

incorporation or organization)

  (I.R.S. Employer
Identification No.)

 

BioVentures Center, 2500 Crosspark Road, Coralville, IA 52241
(Address of principal executive offices) (Zip Code)

 

Issuer’s telephone Number: (805) 966-6566

 

Former address, if changed since last report

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer  Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

The number of shares of registrant’s common stock outstanding, as of February 10, 2025 was 5,437,338,655.

 

 

 

 

 

 

SUNHYDROGEN, INC.

 

INDEX

 

  Page
PART I: FINANCIAL INFORMATION 1
Item 1: Financial Statements (Unaudited) 1
  Condensed Balance Sheets 1
  Condensed Statements of Operations 2
  Condensed Statements of Shareholders’ Equity/(Deficit) 3
  Condensed Statements of Cash Flows 4
  Notes to the Condensed Financial Statements 5
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item 3: Quantitative and Qualitative Disclosures About Market Risk 17
Item 4: Controls and Procedures 18
     
PART II: OTHER INFORMATION 19
Item 1 Legal Proceedings 19
Item 1A: Risk Factors 19
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 3: Defaults Upon Senior Securities 19
Item 4: Mine Safety Disclosures 19
Item 5: Other Information 19
Item 6: Exhibits 19
     
Signatures 20

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

SUNHYDROGEN, INC.

CONDENSED BALANCE SHEETS

 

   December 31,   June 30, 
   2024   2024 
   (unaudited)     
ASSETS        
CURRENT ASSETS        
Cash and cash equivalents  $39,631,955   $39,044,795 
Prepaid expenses   164,585    
-
 
Equity securities, related party   
-
    4,101,402 
           
TOTAL CURRENT ASSETS   39,796,540    43,146,197 
           
OTHER ASSETS          
           
PROPERTY & EQUIPMENT          
Machinery and equipment   36,830    36,830 
Computers and peripherals   11,529    11,529 
Vehicle   135,260    135,260 
    183,619    183,619 
Less: accumulated depreciation   (36,255)   (20,549)
           
NET PROPERTY AND EQUIPMENT   147,364    163,070 
           
INTANGIBLE ASSETS          
Trademark, net of amortization of $885 and $827, respectively   257    315 
Patents, net of amortization of $46,191 and 42,909, respectively   54,952    58,234 
           
TOTAL INTANGIBLE ASSETS   55,209    58,549 
           
TOTAL OTHER ASSETS   202,573    221,619 
           
TOTAL ASSETS  $39,999,113   $43,367,816 
           
LIABILITIES, PREFERRED STOCK SUBJECT TO REDEMPTION AND SHAREHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
Accounts payable and other payables  $361,792   $573,127 
Accrued expenses   161,497    140,558 
Loan payable, related party   
-
    45,829 
           
TOTAL LIABILITIES   523,289    759,514 
           
COMMIMENTS AND CONTINGENCIES   
-
    
-
 
           
Series C 10% Preferred Stock, 6,651 and 8,851 shares issued and outstanding, redeemable value of $665,100 and $885,100, respectively   665,100    885,100 
           
SHAREHOLDERS’ EQUITY          
Preferred Stock, $0.001 par value; 5,000,000 authorized preferred shares   
-
    
-
 
Common Stock, $0.001 par value; 10,000,000,000 authorized common shares 5,437,338,655 and 5,087,245,974 shares issued and outstanding, respectively   5,437,339    5,087,246 
Additional Paid in Capital   130,743,528    128,488,199 
Accumulated deficit   (97,370,143)   (91,852,243)
           
TOTAL SHAREHOLDERS’ EQUITY   38,810,724    41,723,202 
           
TOTAL LIABILITIES, PREFERRED STOCK SUBJECT TO REDEEMPTION AND SHAREHOLDERS’ EQUITY  $39,999,113   $43,367,816 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

1

 

 

SUNHYDROGEN, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

   Three Months Ended
December 31,
   Six Months Ended
December 31,
 
   2024   2023   2024   2023 
                 
REVENUE  $
-
   $
-
   $
-
   $
-
 
                     
OPERATING EXPENSES                    
Selling and Marketing   323    
-
    647    44,000 
General and administrative expenses   621,609    497,844    1,040,353    1,002,505 
Research and development cost   626,318    756,263    1,234,323    1,195,327 
Depreciation and amortization   9,692    10,775    19,046    21,780 
                     
TOTAL OPERATING EXPENSES   1,257,942    1,264,882    2,294,369    2,263,612 
                     
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES)   (1,257,942)   (1,264,882)   (2,294,369)   (2,263,612)
                     
OTHER INCOME/(EXPENSES)                    
Investment income   439,645    484,984    919,368    960,593 
Dividend expense   (39,565)   (22,591)   (40,871)   (43,520)
Unrealized (gain)/loss on change in fair value of investment, related party   (2,613,117)   (2,224,504)   (4,101,402)   (1,938,835)
Realized gain(loss) on redemption of marketable securities   
-
    
-
    
-
    (188,040)
Interest expense   (83)   (1,714)   (626)   (3,405)
                     
TOTAL OTHER INCOME (EXPENSES)   (2,213,120)   (1,763,825)   (3,223,531)   (1,213,207)
                     
NET INCOME (LOSS)  $(3,471,062)  $(3,028,707)  $(5,517,900)  $(3,476,819)
                     
BASIC & DILUTED EARNINGS (LOSS) PER SHARE  $(0.00)  $(0.00)  $(0.00)  $(0.00)
                     
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC & DILUTED   5,303,929,044    5,069,670,749    5,203,191,703    4,965,620,378 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

2

 

 

SUNHYDROGEN, INC.

CONDENSED STATEMENTS OF SHAREHOLDER’S DEFICIT

FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2024 AND 2023

 

                       Additional         
   Preferred stock       Common stock   Paid-in   Accumulated     
   Shares   Amount   Mezzanine   Shares   Amount   Capital   Deficit   Total 
Balance at June 30, 2023   
-
   $
-
   $1,095,100    4,821,298,283   $4,821,298   $126,889,423   $(81,971,040)  $49,739,681 
Issuance of common stock upon partial conversion of purchase agreement for cash   
-
    
-
    
-
    18,684,057    18,684    225,291    
-
    243,975 
Issuance of common stock upon conversion of Series C Preferred stock   
-
    
-
    (210,000)   221,052,632    221,053    (11,053)   
-
    210,000 
Stock compensation expense   -    
-
    
-
    -    
-
    72,481    
-
    72,481 
Net Loss   -    
-
    
-
    -    
-
    
-
    (448,112)   (448,112)
Balance at September 30, 2023 (unaudited)   
-
    
-
    885,100    5,061,034,972    5,061,035    127,176,142    (82,419,152)   49,818,025 
Issuance of common stock upon partial conversion of purchase agreement for cash   
-
              31,779,661    31,780    261,195    
-
    292,975 
Stock compensation expense   -              -    
-
    72,482    
-
    72,482 
Net Loss   -    -    
-
    -    
-
    
-
    (3,028,707)   (3,028,707)
Balance at December 31, 2023 (unaudited)   
-
    
-
    885,100    5,092,814,633    5,092,815    127,509,819    (85,447,859)   47,154,775 
                                         
Balance at June 30, 2024   
-
   $
-
   $885,100    5,087,245,974   $5,087,246   $128,488,199   $(91,852,243)  $41,723,202 
Issuance of common stock upon partial conversion of purchase agreement for cash   
-
    
-
    
-
    118,513,734    118,514    2,083,411    
-
    2,201,925 
Stock compensation expense   -    
-
    
-
    -    
-
    9,981    
-
    9,981 
Net Loss   -    
-
    
-
    -    
-
    
-
    (2,046,838)   (2,046,838)
Balance at September 30, 2024 (unaudited)   
-
    
-
    885,100    5,205,759,708    5,205,760    130,581,591    (93,899,081)   41,888,270 
Preferred stock converted to common stock   
-
    -    (220,000)   231,578,947    231,579    (11,579)   -    220,000 
Stock compensation expense   -    -    -    -    -    173,516    -    173,516 
Net Loss   -    
-
    
-
    -    
-
    
-
    (3,471,062)   (3,471,062)
Balance at December 31, 2024 (unaudited)   
-
   $
-
   $665,100    5,437,338,655   $5,437,339   $130,743,528   $(97,370,143)  $38,810,724 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

 

SUNHYDROGEN, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Six Months Ended
December 31,
 
   2024   2023 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net Income (Loss)   (5,517,900)   (3,476,819)
Adjustment to reconcile net income (loss) to net cash (used in) provided by operating activities          
Depreciation & amortization expense   19,046    21,780 
Stock based compensation expense for services   183,497    144,963 
Loss on redemption of marketable securities   
-
    188,040 
Unrealized (gain)/loss on change in fair value of investment, related party   4,101,402    1,938,835 
Change in assets and liabilities :          
Interest receivable on certificate of deposit   
-
    (61,200)
Prepaid expense   (164,585)   
-
 
Accounts payable   (211,335)   236,392 
Accrued expenses   20,939    59,057 
NET CASH USED IN OPERATING ACTIVITIES   (1,568,936)   (948,952)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Marketable securities purchased   
-
    (168,733,113)
Marketable securities redeemed   
-
    164,145,423 
Purchase of certificate of deposit   
-
    (5,000,000)
Purchase of marketable securities unsettled   
-
    4,587,690 
Redemption of short term investments in corporate securities   
-
    3,000,000 
NET CASH USED IN INVESTING ACTIVITIES   
-
    (2,000,000)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayment of related party note payable   (45,829)   (52,333)
Net proceeds from common stock purchase agreements   2,201,925    536,950 
NET CASH PROVIDED BY FINANCING ACTIVITIES   2,156,096    484,617 
           
Net increase (decrease) in cash and cash equivalents   587,160    (2,464,335)
Cash and cash equivalents - beginning of period   39,044,795    37,185,989 
Cash and cash equivalents - end of period   39,631,955    34,721,654 
           
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION          
Interest paid  $626   $3,406 
Taxes paid  $
-
   $
-
 
           
SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS          
Conversion of Series C Preferred shares to common stock  $220,000.00   $210,000 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4

 

 

SUNHYDROGEN, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

AS OF DECEMBER 31, 2024

(Unaudited)

 

1.ORGANIZATION AND LINE OF BUSINESS

 

Organization

 

SunHydrogen, Inc. (the “Company”) was incorporated in the state of Nevada on February 18, 2009. The Company, based in Coralville, IA began operations on February 19, 2009.

 

Line of Business

 

The company is currently developing a novel solar-powered nanoparticle system that mimics photosynthesis to separate hydrogen from water. We intend for technology of this system to be used for the production of renewable hydrogen to produce renewable electricity and hydrogen for fuel cells and other applications where hydrogen is used.

 

SunHydrogen is developing an efficient and cost-effective way to produce green hydrogen using sunlight and any source of water. Just like a solar panel is comprised of multiple cells that generate electricity, our hydrogen panel encases multiple hydrogen generators immersed in water. Each hydrogen generator contains billions of electroplated nanoparticles, autonomously splitting water into hydrogen and oxygen. We believe our technology has the potential to be one of – if not the most – economical green hydrogen solutions: Unlike traditional water electrolysis for hydrogen, our process requires no external power other than sunlight and uses efficient and low-cost materials.

 

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2024 are not necessarily indicative of the results that may be expected for the year ended June 30, 2025. For further information refer to the financial statements and footnotes thereto included in the Company’s Form 10-K for the year ended June 30, 2024.

 

Cash and Cash Equivalent

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

The following table provides detail of our cash and cash equivalents.

 

   December 31,
2024
    

June 30,
2024

 
Cash  $29,630,222   $29,365,997 
U.S. Treasury bills   10,001,733    9,678,798 
Total cash and cash equivalents  $39,631,955   $39,044,795 

 

The U.S. Treasury bills have a credit quality indicator of AA/A.

 

5

 

 

Concentration risk

 

Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Company (FDIC) limits. At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of the FDIC limits. As of December 31, 2024, the cash balance in excess of the FDIC limits was $37,834,640. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.

 

Use of Estimates

 

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, fair value of financial instruments, and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

 

Property and Equipment

 

Property and equipment are stated at cost and are depreciated using straight line over their estimated useful lives.

 

Computers and peripheral equipment   5 Years 
Vehicle   5 Years 

 

The Company recognized depreciation expense of $15,706 and $18,411 for the six months ended December 31, 2024 and 2023, respectively. 

 

Intangible Assets

 

The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives.

 

    Useful Lives   December 31,
2024
     June 30,
2024
 
                 
Trademark-gross   10 years   $ 1,142     $ 1,142  
Less accumulated amortization         (885 )     (827 )
Trademark-net       $ 257     $ 315  
                     
Patents-gross   15 years   $ 101,143     $ 101,143  
Less accumulated amortization         (46,191 )     (42,909 )
Patents-net       $ 54,952     $ 58,234  

 

The Company recognized amortization expense of $3,340 and $3,369 for the six months ended December 31, 2024 and 2023, respectively.

 

Future Amortization Expense

 

Year  Amount 
2025 (remaining)  $3,340 
2026   6,622 
2027   6,622 
2028   6,650 
2029   6,565 
Thereafter   25,410 
   $55,209 

 

6

 

 

Impairment of Long-lived Assets

 

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

 

When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended December 31, 2024 and 2023, the Company determined no impairment was required.

 

Net Earnings (Loss) per Share Calculations

 

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the three and six months ended December 31, 2024 and 2023. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards, if dilutive. 

 

The total potential common shares as of December 31, 2024, include 255,465,911 stock options, 78,095,239 common stock purchase warrants, and 700,105,263 common shares issuable upon conversion of the outstanding 6,651 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is antidilutive. 

 

The total potential common shares as of December 31, 2023, include 218,394,499 stock options, 86,495,239 common stock purchase warrants, and 931,684,211 common shares issuable upon conversion of the outstanding 8,851 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is antidilutive.

 

Stock Based Compensation

 

The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.

 

Warrant Accounting 

 

The Company accounts for warrants to purchase shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation model.

 

7

 

 

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate that value. As of December 31, 2024, the amounts reported for cash, accounts payable and other payables, and accrued expenses approximate the fair value because of their short maturities.

 

We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

 

These tiers include:

 

  Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.

 

  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active.

 

  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows (See Note 7):

 

December 31, 2024

 

    Total    (Level 1)    (Level 2)    (Level 3) 
Assets:                    
Equity securities, related party  $
-
   $
-
   $
-
   $
-
 
   $
-
   $
-
   $
-
   $
-
 

 

June 30, 2024

 

   Total   (Level 1)   (Level 2)   (Level 3) 
Assets:                
Equity securities, related party  $4,101,402   $
       -
   $4,101,402   $
        -
 
   $4,101,402   $
-
   $4,101,402   $
-
 

 

As of December 31, 2024, the Equity securities, related party had a fair value of $0 which was measured using a level 3 input due to the underlying securities no longer trading on an active stock exchange (See Note 7).

 

Research and Development

 

Research and development costs are expensed as incurred.  Total research and development costs were $1,234,323 and $1,195,327 for the six months ended December 31, 2024 and 2023, respectively.

 

Advertising and Marketing

 

Advertising and marketing cost are expensed as incurred. Total advertising and marketing costs were $647 and $44,000 for the six months ended December 31, 2024 and 2023, respectively.

 

8

 

 

Accounting for Derivatives

 

The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates.

 

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

 

Recently Issued Accounting Pronouncements

 

Management believes that no recently issued accounting standards, which are not yet effective, would have a material impact on the accompanying unaudited financial statements as of December 31, 2024, if adopted at this time.

 

Reclassification

 

Certain accounts from prior periods have been reclassified to conform to the current period presentation.

 

3.PREFERRED STOCK

 

Series C Preferred Stock

 

On December 15, 2021, the Company filed a certificate of designation of Series C Preferred Stock with the Secretary of State of Nevada, designating 17,000 shares of preferred stock as Series C Preferred Stock. Each share of Series C Preferred Stock has a stated value of $100 and is convertible into shares of common stock of the Company at a conversion price of $0.00095. The Series C Preferred Stock holders are entitled to receive out of any funds and assets of the Company legally available prior and in preference to any declaration or payment of any dividend on the common stock of the Company, cumulative dividends, at an annual rate of 10% of the stated value, payable in cash or shares of common stock. In the event the Company declares or pays a dividend on its shares of common stock (other than dividend payable in shares of common stock), the holders of Series C Preferred Stock will also be entitled to receive payment of such dividend on an as--converted basis. The Series C Preferred Stock confers no voting rights on holders, except with respect to matters that materially and adversely affect the voting powers, rights or preferences of the Series C Preferred Stock or as otherwise required by applicable law. Upon liquidation, dissolution and winding up of the Company, the holders of Series C Preferred Stock will be entitled to receive, before any payments will made or any assets distributed to the holders of the common stock, the stated value of the Series C Preferred Shares plus any declared but unpaid dividends. No other current or future equity holders of the Company will have higher priority of liquidation preference than holders of Series C Preferred Stock.

 

The Series C Preferred Stock is presented as mezzanine equity because it is redeemable at a fixed or determinable amount upon an event that is outside of the Company’s control.

 

During the six months ended December 31, 2024, an investor converted 2,200 preferred shares with a stated value of $220,000, at a conversion price of $0.00095, into 231,578,947 common shares. No gain or loss was recognized in the financial statements.

 

During the six months ended December 31, 2023, an investor converted 2,100 preferred shares with a stated value of $210,000, at a conversion price of $0.00095, into 221,052,632 common shares. No gain or loss was recognized in the financial statements.

 

As of December 31, 2024 and June 30, 2024, the Company had 6,651 and 8,851 shares of Series C Preferred Stock outstanding, respectively. The fair value of the outstanding shares was $665,100 and $885,100, respectively. 

 

9

 

 

4.COMMON STOCK

 

Six Months Ended December 31, 2024

 

On November 11, 2022, the Company entered into a Purchase Agreement with an investor for the sale of up to $45,000,000 of shares of common stock. For the six months ended December 31, 2024, the Company issued 118,513,734 shares of common stock for $2,250,000 under the purchase agreement at prices of $0.0156 - $0.02024, pursuant to purchase notices received from the investor. The finance cost of $48,075 was deducted from the gross proceeds received, leaving net proceeds of $2,201,925.

 

On November 22, 2024, the Company issued 231,578,947 shares of common stock, upon conversion of 2,200 shares of preferred stock with a stated value of $220,000 at a conversion price of $0.00095.

 

Six Months Ended December 31, 2023

 

On November 11, 2022, the Company entered into a Purchase Agreement with an investor for the sale of up to $45,000,000 of common stock. For the six months ended December 31, 2023, the Company issued 50,463,718 shares of common stock for $550,000 under the purchase agreement at prices of $0.0094 - $0.0134, pursuant to purchase notices received from the investor. The finance cost of $13,050 was deducted from the gross proceeds received, leaving gross proceeds of $536,950.

 

On September 8, 2023, the Company issued 221,052,632 shares of common stock, upon conversion of 2,100 shares of preferred stock with a stated value of $210,000 at a conversion price of $0.00095

 

5.STOCK INCENTIVE PLANS

 

2019 Equity Stock Incentive Plan

 

On December 17, 2018, the Board of Directors approved and adopted the 2019 Equity Incentive Plan (“the 2019 Plan”), with 300,000,000 shares reserved for issuance. The purpose of the 2019 Plan is to promote the success of the Company and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain, and reward selected employees and other eligible persons. The awards are performance-based compensation that are granted under the 2019 Plan as incentive stock options (ISO) or nonqualified stock options. The per share exercise price for each option shall not be less than 100% of the fair market value of a share of common stock on the date of grant of the option. The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing cost.

 

As of December 31, 2024, under the 2019 Equity Incentive Plan, there were 285,270,561 stock options and shares issued, with 14,729,439 shares remaining available for issuance.

 

2022 Equity Stock Incentive Plan

 

On January 27, 2022, the Company adopted the 2022 Equity Incentive Plan, to enable the Company to attract and retain the types of employees, consultants, and directors who will contribute to the Company’s long-range success. The maximum number of shares of common stock that may be issued under the 2022 Plan is initially 400,000,000. The number of shares will automatically be increased on the first day of the Company’s fiscal year beginning in 2023 so that the total number of shares issuable equals fifteen percent (15%) of the Company’s fully diluted capitalization on the first day of the Company’s fiscal year, unless the Board adopts a resolution providing that the number of shares issuable under the 2022 Plan shall not be so increased.

 

As of July 1, 2024, the maximum number of shares issuable under the 2022 Equity Incentive Plan was increased to 953,548,700 shares, based on the Company’s fully diluted capitalization of 6,356,991,335. As of December 31, 2024, there were 448,600,000 stock options and shares issued, with 504,948,700 shares remaining available for issuance.

 

10

 

 

6.STOCK OPTIONS AND WARRANTS

 

Options

 

Transactions involving our options are summarized as follows:

 

           Weighted 
       Weighted   Average 
       Average   Grant-Date 
   Number of   Exercise   Per Share 
   Options   Price   Fair Value 
Options outstanding at June 30, 2024   266,894,499   $0.011   $0.011 
Granted   275,000,000   $0.017   $0.013 
Canceled/Expired   (6,928,588)  $0.010   $0.010 
Exercised   
-
   $
-
   $- 
Options outstanding at December 31, 2024   534,965,911   $0.0139   $0.012 

 

Details of our options outstanding as of December 31, 2024, is as follows:

 

Options Exercisable   Weighted Average
Exercise Price of
Options Exercisable
   Weighted Average
Contractual Life of
Options Exercisable
(Years)
   Weighted Average
Contractual Life of
Options Outstanding
(Years)
 
 255,465,911    0.011    2.15    4.85 

  

Total stock compensation expense related to the options for the six months ended December, 2024 and 2023, was $183,497 and $144,963, respectively. As of December 31, 2024 there was approximately $3.5 million of unrecognized compensation cost related to the Options, which is expected to be recognized over a remaining weighted-average vesting period of approximately 1.41 years.

 

Warrants

 

Transactions involving our warrants are summarized as follows:

 

       Weighted 
   Number of
Shares
   Average
Exercise Price
 
Warrants outstanding at June 30, 2024   78,095,239   $0.121 
Issued   
-
   $
-
 
Canceled/Expired   
-
   $
-
 
Exercised   
-
   $
-
 
Warrants outstanding at December 31, 2024   78,095,239   $0.121 

 

Details of our warrants outstanding as of December 31, 2024, is as follows:

 

Warrants Exercisable   Weighted Average Contractual Life of Warrants
Outstanding and Exercisable (Years)
 
 78,095,239    1.17 

 

11

 

 

7. EQUITY SECURITIES, RELATED PARTY

 

On November 11, 2022, the Company entered into a subscription agreement with TECO 2030 ASA (“TECO”). TECO was a Norwegian based clean tech company developing zero-emission technology for the maritime and heavy industry. They were developing PEM hydrogen fuel cell stacks and PEM hydrogen fuel cell modules, that enable ships and other heavy-duty applications to become emissions-free. TECO was listed on Euronext Growth on Oslo Stock Exchange under the ticker TECO. Pursuant to the subscription agreement, the Company purchased 13,443,875 shares of TECO stock for an aggregate consideration of $7 million in USD, at an exchange rate of NOK 10.4094. The shares purchased are adjusted to fair value based on unrealized gain or loss at the end of each period. At the time of this transaction, the Company and TECO became related parties due to the Company owning an 8.3% interest in TECO. Subsequent to the equity purchase, Timothy Young, CEO of the Company, was elected to the board of TECO in January of 2023.

 

Also, on November 11, 2022 the Company purchased a bond receivable of TECO for a subscription amount of $3 million. The issuance of the bond receivable was through a Tap Issue Addendum to TECO’s secured convertible notes agreement dated June 1, 2022, pursuant to which Nordic Trustee AS was acting as the security agent on behalf of the note holders. The bond receivable would have matured on June 1, 2025, and would have been converted into shares at a rate of NOK 5.0868 per share. The note bore interest at the rate of 8% per annum, which was paid quarterly in arrears. For the six months ended December 31, 2023, the Company recognized interest income of $114,652.

 

In April of 2024, all investors of TECO bonds received an option to convert their bonds to receive one share for every two NOK. On May 24, 2024 the Company agreed to the terms and conversion, and agreed to receive 15,884,744 shares of TECO stock in exchange for the convertible bond receivable of $3,000,000 and unpaid interest. The bond receivable had a principal amount of NOK 31,228,200, and accrued and unpaid interest up to May 24, 2024 of NOK 541,289, for a total of NOK 31,769,489. The value of the shares converted on May 24, 2024 was $3,139,302 with contributed capital gain on conversion of convertible bond of $85,815 and interest received of $53,487.

 

On September 10, 2024, after a delay to allow time for legal review and clarification of the investment statements, the bond was returned. Upon receipt of the 15,884,744 shares, the Company owned a total of 29,328,619 shares, which as of September 30, 2024 represented approximately 13.29% of the outstanding shares of TECO.

 

The CEO of the Company elected to not seek reelection to the board of directors at the annual general meeting in June and is no longer a director of TECO after June 19, 2024. The CEO of the Company never received compensation of any kind for his role as director from January of 2023 through June 19, 2024.

 

During December 2024, it came to the Company’s attention that TECO filed for bankruptcy and their shares were suspended from trading on the Euronext Growth on Oslo Stock Exchange. In January 2025, TECO was delisted. Based on these events, the Company determined the fair value of their shares was $0 as of December 31, 2024.

 

On December 17, 2024, the Company entered a share allocation agreement with TECO HOLDING AS, in which Bacchus AS (“Newco” and a wholly owned subsidiary of TECO HOLDINGS AS) intends to acquire the shares and other assets owned by TECO 2030 ASA. TECO HOLDINGS AS then agreed to transfer shares in Newco equal to 13.32% of the total shares of Newco to the Company free of charge, encumbrances, and other liens. Concurrently with the transfer of shares under the allocation agreement, a representative of the Company shall, whenever preferred, be appointed to the board of directors of Newco. As of December 31, 2024, due to Newco recently being formed and there being no readily determinable fair value, the Company determined the fair value of the Newco shares was $0.

 

The following table summarizes our equity investments in TECO:

 

Date of Investment  Number of
Shares
   Cost Basis   Fair Value
as of
June 30,
2024
   Unrealized Loss   Fair Value
as of
December 31,
2024
 
November 24, 2022   13,443,875   $7,000,000   $1,880,032   $(1,880,032)  $
-
 
May 24, 2024   15,884,744    3,139,302    2,221,370    (2,221,370)   
-
 
Total   29,328,619   $10,139,302   $4,101,402   $(4,101,402)  $
-
 

 

12

 

 

8.INVESTMENT INCOME

 

The following table summarizes our investment income.

 

   December 31,
2024
   December 31,
2023
 
Interest earned on cash (NOTE 2)  $675,207   $52,468 
Interest earned on Treasury Bills (NOTE 2)   240,475    664,157 
Interest earned on Certificates of Deposit (NOTE 9)   
-
    61,200 
Interest earned on Corporate Bonds   
-
    54,375 
Interest earned on TECO bond (NOTE 7)   
-
    114,652 
Dividends and other   3,686    13,741 
Total investment income  $919,368   $960,593 

 

9.SHORT TERM INVESTMENTS

 

On September 12, 2023, the Company invested in a $5,000,000 certificate of deposit (CD), which matured on March 12, 2024. CDs should be reported as part of cash and cash equivalents at cost plus accrued interest if less than 90 days from the purchase date, and on its own line in the financial statements if the purchase is greater than 90 days. The CD has been classified as a short-term investment due to the length of time to maturity at acquisition and was measured using Level 2. The CD was reinvested upon maturity. The Company recognized interest income of $61,200 which was reported in the Company’s financial statements as of December 31, 2023.

 

10.COMMITMENTS AND CONTINGENCIES

 

Effective October 1, 2024, the Company extended its research agreement with the University of Iowa through September 30, 2025. As consideration under the research agreement, the University of Iowa will receive a maximum of $302,459 from the Company in four equal installments of $75,615. The agreement can be terminated by either party upon sixty (60) days prior written notice to the other. As of December 31, 2024, there is a balance due of $75,615 per the agreement.

 

Effective October 1, 2024, the Company extended its research agreement with the University of Michigan through September 30, 2025. As consideration under the research agreement, the University of Michigan will receive a maximum of $252,246 from the Company. In the event of early termination by the Sponsor, the Sponsor will pay all costs accrued by the University as of the date of termination, including non-cancellable obligations. As of December 31, 2024, there is a balance due of $63,062 per the agreement and $40,091 per the prior amended research agreement for a total of $103,153.

 

The Company began renting lab space in February 2022. The lab rental is on a month-to-month basis and is cancellable with a thirty (30) day notice. On April 1, 2024, the Company renewed the space needed for its lab work at a monthly rent of $6,400 per month. Due to the rental being month-to-month, ASC 842 lease accounting is not applicable.

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s financial position or results of operation.

 

11.RELATED PARTY

 

Shareholders Loan

 

During the period ended December 31, 2022, the Company entered into a $211,750 loan with the Company’s CEO for the repayment of accrued salary expense. The loan bore interest of five percent (5%) and was to be repaid with monthly payments of $9,290, including interest and principal over a two-year period. As of December 31, 2024 and June 30, 2024, the principal balance remaining on the loan was $0 and $45,829, respectively and interest paid during the six months ended December 31, 2024 and 2023 was $620 and $3,405, respectively.

 

Other Related Party Activity

 

See Note 7 for related party transactions with respect to TECO 2030 A.S.A. and Newco.

 

12.SUBSEQUENT EVENTS

 

Management evaluated subsequent events as of the date of the financial statements pursuant to ASC TOPIC 855 and had the following subsequent events to report.

 

13

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Cautionary Statement Regarding Forward-Looking Statements

 

The information in this report may contain forward-looking statements. These forward-looking statements involve risks and uncertainties, including statements regarding our capital needs, business strategy and expectations. Any statements that are not of historical fact may be deemed to be forward-looking statements. These forward-looking statements involve substantial risks and uncertainties. In some cases you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue”, the negative of the terms or other comparable terminology. Actual events or results may differ materially from the anticipated results or other expectations expressed in the forward-looking statements. In evaluating these statements, you should consider various factors, including the risks included from time to time in our reports filed with the Securities and Exchange Commission, or the SEC. These factors may cause our actual results to differ materially from any forward-looking statements. We disclaim any obligation to publicly update these statements, or disclose any difference between actual results and those reflected in these statements, except as may be required under applicable law.

 

Unless the context otherwise requires, references in this Form 10-Q to “we,” “us,” “our,” “SunHydrogen” or the “Company” refer to SunHydrogen, Inc.

 

Overview

 

At SunHydrogen, our goal is to replace fossil fuels with clean, renewable hydrogen.

 

Hydrogen is the most abundant chemical element in the universe. When hydrogen fuel is used to power transportation and industry, the only byproduct left behind is pure water, unlike hydrocarbon fuels such as oil, coal and natural gas that emit carbon dioxide and other harmful pollutants into the atmosphere. However, naturally occurring elemental hydrogen is rare - so rare, in fact, that today about 95% of hydrogen is produced from steam reforming of natural gas (Source: US Department of Energy, Hydrogen Fuel Basics). This process is both economically and environmentally unsound.

 

The SunHydrogen solution offers an efficient and cost-effective way to produce truly green hydrogen using sunlight and any source of water. Our core technology is a self-contained, nanoparticle-based hydrogen generator that mimics photosynthesis to split water molecules, resulting in hydrogen. By optimizing the science of water electrolysis at the nano-level, we believe we have developed a low-cost method to potentially produce environmentally friendly renewable hydrogen.

 

We believe renewable hydrogen has already proven itself to be a key solution in helping the world meet climate targets, and we believe our technology potentially offers solutions to the challenges that the hydrogen future presents, including cost of production and transportation.

 

Because our process only requires sunlight and water, our technology can be installed near the point of hydrogen use. This eliminates the need for pipelines and trucks that result in high carbon emissions and high capital investment. Additionally, because our process directly uses the electrical charges created by sunlight to generate hydrogen, our nanoparticle technology does not rely on grid power or require the costly power electronics that conventional electrolyzers do. Lastly, our planned scalable system configuration of many individual hydrogen-generating panels ensures redundancy, security and stability.

 

14

 

 

With a target cost of $2.50/kg., we aspire for our technology to be cost-competitive with brown hydrogen and below the cost of clean hydrogen competitors. We believe our solution has the potential to clear a path for green hydrogen to compete with natural gas hydrogen and gain mass market acceptance as a true replacement for fossil fuels.

 

Our technology is primarily developed at three laboratories - our independent laboratory in Coralville, Iowa, the SunHydrogen laboratory at the University of Iowa, and the Singh laboratory at University of Michigan.

 

Additionally, in parallel to the ongoing development of our own technology, we may begin pursuing synergistic strategic investments in the hydrogen space. SunHydrogen is committed to furthering renewable hydrogen technology to grow the hydrogen ecosystem, and we are actively pursuing opportunities for investment and acquisition of complimentary hydrogen technologies.

 

Critical Accounting Policies

 

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using the Binomial valuation option pricing model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described items, are reasonable.

 

Use of Estimates

 

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, Binomial lattice valuation model inputs, derivative liabilities and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

 

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2024, the amounts reported for cash, investment in affiliate, accrued interest and other expenses, notes payables, and derivative liability approximate the fair value because of their short maturities.

 

We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

Recently Issued Accounting Pronouncements

 

Management reviewed currently issued pronouncements during the six months ended December 31, 2024, and does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. Pronouncements are disclosed in notes to the financial statements.

 

15

 

 

Results of Operations for the Three Months ended December 31, 2024 compared to Three Months Ended December 31, 2023

 

Operating Expenses

 

Operating expenses for the three months ended December 31, 2024 were $1,257,942, compared to $1,264,882 for the three months ended December 31, 2023. The net change of $6,940 in operating expenses consisted primarily of increases in general and administrative expenses offset by decreases in research and development costs.

 

Other Income/(Expenses)

 

Other income and (expenses) for the three months ended December 31, 2024 were $(2,213,120), compared to $(1,763,825) for the three months ended December 31, 2023. The decrease in other income of $449,295 was the result of a larger unrealized loss on the Company’s investment in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to in the prior year and a decrease in investment income in the current period compared to the prior year.

 

Net Loss

 

For the three months ended December 31, 2024, our net loss was $3,471,062, compared to a net loss of $3,028,707 for the three months ended December 31, 2023. The increase in net loss of $442,355 was primarily due to an increase in the unrealized loss on the Company’s investment in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to the prior year. These equity securities are measured at fair value on a recurring basis. In addition, the Company has not generated any revenues. 

 

Results of Operations for the Six Months ended December 31, 2024 compared to Six Months Ended December 31, 2023

 

Operating Expenses

 

Operating expenses for the six months ended December 31, 2024 were $2,294,369, compared to $2,263,612 for the six months ended December 31, 2023. The net change of $30,757 in operating expenses consisted primarily of an increase in research and development costs and general and administrative expenses partially offset by decreases in selling and marketing expenses.

 

Other Income/(Expenses)

 

Other income and (expenses) for the six months ended December 31, 2024 were $(3,223,531), compared to $(1,213,207) for the six months ended December 31, 2023. The decrease in other income of $2,010,324 was primarily the result of a larger unrealized loss on the Company’s investment in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to the prior year partially offset by a realized loss on redemption of marketable securities in the prior year with no similar transactions in the current year.

 

Net Loss

 

For the six months ended December 31, 2024, our net loss was $5,517,900, compared to a net loss of $3,476,819 for the six months ended December 31, 2023. The increase in net loss of $2,041,081 was primarily due to an increase in the unrealized loss on the Company’s investment in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to the prior year. These equity securities are measured at fair value on a recurring basis. In addition, the Company has not generated any revenues. 

 

16

 

 

Liquidity and Capital Resources

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

 

As of December 31, 2024, we had working capital of $39,273,251, compared to $42,386,683 as of June 30, 2024. This decrease in working capital of $3,113,432 was primarily due to a decrease in equity securities, related party.

 

Cash used in operating activities was $1,568,936 for the six months ended December 31, 2024, compared to $948,952 for the six months ended December 31, 2023. The net increase of $619,984 in cash used in operating activities was due to increases in the net loss, prepaid expenses, accounts payable, and decrease in loss on redemption of marketable securities offset by an increase in unrealized loss in equity securities, related party. The Company has had no revenues.

 

Cash used in investing activities during the six months ended December 31, 2024 and December 31, 2023 was $0 and $2,000,000, respectively. The net decrease of $2,000,000 in cash used in investing activities was due to the purchase of certificate of deposits offset by the redemption of short-term investments in corporate securities during the six months ended December 31, 2023 with no similar transactions in the six months ended December 31, 2024.

 

Cash provided by financing activities during the six months ended December 31, 2024 and December 31, 2023 was $2,156,096 and $484,617, respectively. The net increase of $1,671,479 in cash provided by financing activities was due to increased proceeds from a Purchase Agreement entered with an investor for the sale of up to $45,000,000 of common stock.

 

Our ability to continue as a going concern is dependent upon raising capital through financing transactions and future revenue. Our capital needs have primarily been met from the proceeds of private placements and registered offerings of our securities, as we have not generated any revenues to date.

 

We have historically obtained funding from investors, through private placements and registered offerings of equity and debt securities. Management believes that the Company will be able to continue to raise funds through the sale of its securities to its existing shareholders and prospective new investors, which will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the Company to continue to develop its core business. There can be no assurance that we will be able to continue raising the required capital for our operations on terms and conditions that are acceptable to us, or at all. If we are unable to obtain sufficient funds, we may be forced to curtail and/or cease our operation.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, result of operations, liquidity or capital expenditures.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 

17

 

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our CEO and our Acting CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our CEO and our Acting CFO concluded that, due to the material weakness described below, our disclosure controls and procedures as of the end of the period covered by this report were not effective to ensure that information required to be disclosed is made known to management and others, as appropriate, to allow timely decision regarding required disclosure and that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms and (ii) accumulated and communicated to our management, including our CEO and Acting CFO, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, including our principal executive officer and acting principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. To address the material weaknesses, we performed additional analysis and other post-closing procedures in an effort to ensure our financial statements included in this report have been prepared in accordance with generally accepted accounting principles. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

 

As of December 31, 2024, due to the inherent issue of segregation of duties in a small company, we have relied heavily on entity or management review controls and engaged an outside financial consultant to lessen the issue of segregation of duties over accounting, financial close procedures and controls over financial statement disclosure. Accordingly, management has determined that this control deficiency constitutes a material weakness.

 

Changes in Internal Control Over Financial Reporting

 

There was no change to our internal control over financial reporting that occurred during our fiscal quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

18

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not currently a party to, nor is any of our property currently the subject of, any material legal proceeding.

 

Item 1A. Risk Factors.

 

There are no material changes from the risk factors previously disclosed in our annual report on Form 10-K filed with the SEC on September 30, 2024.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

During the quarter ended December 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

Item 6. Exhibits.

 

Exhibit No.   Description
31.1*   Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Sarbanes-Oxley Section 302*
32.1**   Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to 18 U.S.C. Section 1350**
101*   Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.
104*   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.

 

*Filed herewith

 

**Furnished herewith

 

19

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

February 10, 2025 SUNHYDROGEN, INC.
     
  By: /s/ Timothy Young
    Timothy Young
    Chief Executive Officer and
    Acting Chief Financial Officer
    (Principal Executive Officer,
    Principal Financial Officer and
    Principal Accounting Officer)

 

20

 

0001481028 false 2025 Q2 --06-30 0001481028 2024-07-01 2024-12-31 0001481028 2025-02-10 0001481028 2024-12-31 0001481028 2024-06-30 0001481028 us-gaap:RelatedPartyMember 2024-12-31 0001481028 us-gaap:RelatedPartyMember 2024-06-30 0001481028 us-gaap:TrademarksMember 2024-12-31 0001481028 us-gaap:TrademarksMember 2024-06-30 0001481028 us-gaap:TradeSecretsMember 2024-12-31 0001481028 us-gaap:TradeSecretsMember 2024-06-30 0001481028 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001481028 us-gaap:SeriesCPreferredStockMember 2024-06-30 0001481028 2024-10-01 2024-12-31 0001481028 2023-10-01 2023-12-31 0001481028 2023-07-01 2023-12-31 0001481028 us-gaap:PreferredStockMember 2023-06-30 0001481028 hysr:MezzanineMember 2023-06-30 0001481028 us-gaap:CommonStockMember 2023-06-30 0001481028 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001481028 us-gaap:RetainedEarningsMember 2023-06-30 0001481028 2023-06-30 0001481028 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001481028 hysr:MezzanineMember 2023-07-01 2023-09-30 0001481028 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001481028 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001481028 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001481028 2023-07-01 2023-09-30 0001481028 us-gaap:PreferredStockMember 2023-09-30 0001481028 hysr:MezzanineMember 2023-09-30 0001481028 us-gaap:CommonStockMember 2023-09-30 0001481028 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001481028 us-gaap:RetainedEarningsMember 2023-09-30 0001481028 2023-09-30 0001481028 us-gaap:PreferredStockMember 2023-10-01 2023-12-31 0001481028 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001481028 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001481028 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001481028 hysr:MezzanineMember 2023-10-01 2023-12-31 0001481028 us-gaap:PreferredStockMember 2023-12-31 0001481028 hysr:MezzanineMember 2023-12-31 0001481028 us-gaap:CommonStockMember 2023-12-31 0001481028 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001481028 us-gaap:RetainedEarningsMember 2023-12-31 0001481028 2023-12-31 0001481028 us-gaap:PreferredStockMember 2024-06-30 0001481028 hysr:MezzanineMember 2024-06-30 0001481028 us-gaap:CommonStockMember 2024-06-30 0001481028 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001481028 us-gaap:RetainedEarningsMember 2024-06-30 0001481028 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001481028 hysr:MezzanineMember 2024-07-01 2024-09-30 0001481028 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001481028 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001481028 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001481028 2024-07-01 2024-09-30 0001481028 us-gaap:PreferredStockMember 2024-09-30 0001481028 hysr:MezzanineMember 2024-09-30 0001481028 us-gaap:CommonStockMember 2024-09-30 0001481028 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001481028 us-gaap:RetainedEarningsMember 2024-09-30 0001481028 2024-09-30 0001481028 us-gaap:PreferredStockMember 2024-10-01 2024-12-31 0001481028 hysr:MezzanineMember 2024-10-01 2024-12-31 0001481028 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001481028 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001481028 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001481028 us-gaap:PreferredStockMember 2024-12-31 0001481028 hysr:MezzanineMember 2024-12-31 0001481028 us-gaap:CommonStockMember 2024-12-31 0001481028 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001481028 us-gaap:RetainedEarningsMember 2024-12-31 0001481028 hysr:StockOptionsMember 2024-07-01 2024-12-31 0001481028 hysr:CommonStockPurchaseWarrantsMember 2024-07-01 2024-12-31 0001481028 us-gaap:CommonStockMember 2024-07-01 2024-12-31 0001481028 us-gaap:SeriesCPreferredStockMember 2024-07-01 2024-12-31 0001481028 hysr:StockOptionsMember 2023-07-01 2023-12-31 0001481028 hysr:CommonStockPurchaseWarrantsMember 2023-07-01 2023-12-31 0001481028 us-gaap:CommonStockMember 2023-07-01 2023-12-31 0001481028 us-gaap:SeriesCPreferredStockMember 2023-07-01 2023-12-31 0001481028 us-gaap:FairValueInputsLevel3Member us-gaap:RelatedPartyMember 2024-12-31 0001481028 us-gaap:CashMember 2024-12-31 0001481028 us-gaap:CashMember 2024-06-30 0001481028 us-gaap:USTreasuryBillSecuritiesMember 2024-12-31 0001481028 us-gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001481028 us-gaap:ComputerEquipmentMember 2024-12-31 0001481028 us-gaap:VehiclesMember 2024-12-31 0001481028 us-gaap:TrademarksMember 2024-12-31 0001481028 us-gaap:TrademarksMember 2024-06-30 0001481028 us-gaap:PatentsMember 2024-12-31 0001481028 us-gaap:PatentsMember 2024-06-30 0001481028 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001481028 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001481028 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001481028 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001481028 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001481028 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001481028 us-gaap:SeriesCPreferredStockMember 2021-12-15 0001481028 us-gaap:SeriesCPreferredStockMember 2021-12-15 2021-12-15 0001481028 us-gaap:PreferredStockMember 2024-07-01 2024-12-31 0001481028 us-gaap:SeriesCPreferredStockMember 2023-07-01 2023-12-31 0001481028 hysr:PurchaseAgreementMember us-gaap:CommonStockMember 2022-11-11 2022-11-11 0001481028 us-gaap:CommonStockMember 2024-07-01 2024-12-31 0001481028 srt:MinimumMember us-gaap:CommonStockMember 2024-07-01 2024-12-31 0001481028 srt:MaximumMember us-gaap:CommonStockMember 2024-07-01 2024-12-31 0001481028 hysr:PurchaseAgreementMember 2024-12-31 0001481028 us-gaap:CommonStockMember 2024-11-22 2024-11-22 0001481028 us-gaap:PreferredStockMember 2024-11-22 2024-11-22 0001481028 us-gaap:PreferredStockMember 2024-11-22 0001481028 us-gaap:CommonStockMember 2022-11-11 2022-11-11 0001481028 us-gaap:CommonStockMember hysr:PurchaseAgreementWithAnInvestorMember 2023-07-01 2023-12-31 0001481028 srt:MinimumMember hysr:PurchaseAgreementWithAnInvestorMember 2023-12-31 0001481028 srt:MaximumMember hysr:PurchaseAgreementWithAnInvestorMember 2023-12-31 0001481028 hysr:PurchaseAgreementWithAnInvestorMember 2023-07-01 2023-12-31 0001481028 us-gaap:CommonStockMember 2023-09-08 2023-09-08 0001481028 us-gaap:PreferredStockMember 2023-09-08 2023-09-08 0001481028 us-gaap:PreferredStockMember 2023-09-08 0001481028 hysr:TwoZeroOneNineEquityIncentivePlanMember us-gaap:StockOptionMember 2018-12-17 0001481028 hysr:TwoZeroOneNineEquityIncentivePlanMember 2018-12-17 2018-12-17 0001481028 hysr:TwoZeroOneNineEquityIncentivePlanMember 2024-07-01 2024-12-31 0001481028 hysr:TwoZeroOneNineEquityIncentivePlanMember 2024-12-31 0001481028 hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember hysr:EquityIncentiveMember 2022-01-27 2022-01-27 0001481028 hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember 2022-01-27 2022-01-27 0001481028 hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember 2024-07-01 0001481028 hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember 2024-07-01 2024-07-01 0001481028 hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember 2024-07-01 2024-12-31 0001481028 hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember 2024-12-31 0001481028 us-gaap:WarrantMember 2024-06-30 0001481028 us-gaap:WarrantMember 2024-07-01 2024-12-31 0001481028 us-gaap:WarrantMember 2024-12-31 0001481028 2022-11-01 2022-11-11 0001481028 2022-11-11 0001481028 2024-05-24 2024-05-24 0001481028 hysr:TECOBondsMember 2024-05-24 2024-05-24 0001481028 hysr:TECOBondsMember us-gaap:InvestorMember 2024-05-24 2024-05-24 0001481028 hysr:TECOBondsMember 2024-09-10 0001481028 2024-09-10 0001481028 hysr:TECOMember 2024-09-30 0001481028 hysr:TECOMember 2024-12-31 0001481028 hysr:NovemberTwentFourTwoThousandTwentyTwoMember hysr:TECOMember 2024-12-31 0001481028 hysr:NovemberTwentFourTwoThousandTwentyTwoMember hysr:TECOMember 2024-06-30 0001481028 hysr:NovemberTwentFourTwoThousandTwentyTwoMember hysr:TECOMember 2024-07-01 2024-12-31 0001481028 hysr:MayTwentyFourTwoThousandTwentyFourMember hysr:TECOMember 2024-12-31 0001481028 hysr:MayTwentyFourTwoThousandTwentyFourMember hysr:TECOMember 2024-06-30 0001481028 hysr:MayTwentyFourTwoThousandTwentyFourMember hysr:TECOMember 2024-07-01 2024-12-31 0001481028 hysr:TECOMember 2024-12-31 0001481028 hysr:TECOMember 2024-06-30 0001481028 hysr:TECOMember 2024-07-01 2024-12-31 0001481028 hysr:InterestEarnedOnCashMember 2024-07-01 2024-12-31 0001481028 hysr:InterestEarnedOnCashMember 2023-07-01 2023-12-31 0001481028 hysr:InterestEarnedOnTreasuryBillsMember 2024-07-01 2024-12-31 0001481028 hysr:InterestEarnedOnTreasuryBillsMember 2023-07-01 2023-12-31 0001481028 hysr:InterestEarnedOnCertificatesOfDepositMember 2024-07-01 2024-12-31 0001481028 hysr:InterestEarnedOnCertificatesOfDepositMember 2023-07-01 2023-12-31 0001481028 hysr:InterestEarnedOnCorporateBondsMember 2024-07-01 2024-12-31 0001481028 hysr:InterestEarnedOnCorporateBondsMember 2023-07-01 2023-12-31 0001481028 hysr:InterestEarnedOnTECOBondMember 2024-07-01 2024-12-31 0001481028 hysr:InterestEarnedOnTECOBondMember 2023-07-01 2023-12-31 0001481028 hysr:DividendsAndOtherMember 2024-07-01 2024-12-31 0001481028 hysr:DividendsAndOtherMember 2023-07-01 2023-12-31 0001481028 2023-09-12 0001481028 us-gaap:CertificatesOfDepositMember 2023-09-12 0001481028 us-gaap:CertificatesOfDepositMember 2023-07-01 2023-12-31 0001481028 hysr:UniversityOfIowaMember 2024-10-01 0001481028 hysr:UniversityOfIowaMember 2024-10-01 2024-10-01 0001481028 hysr:UniversityOfIowaMember 2024-12-31 2024-12-31 0001481028 hysr:UniversityOfMichiganMember 2024-10-01 0001481028 hysr:UniversityOfMichiganMember 2024-07-01 2024-12-31 0001481028 2024-04-01 0001481028 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2022-12-31 0001481028 2022-07-01 2022-12-31 0001481028 hysr:LoanMember 2022-07-01 2022-12-31 0001481028 hysr:LoanMember 2024-07-01 2024-12-31 0001481028 hysr:LoanMember 2023-07-01 2024-06-30 0001481028 hysr:LoanMember 2023-07-01 2023-12-31 xbrli:shares iso4217:USD xbrli:pure iso4217:USD xbrli:shares iso4217:NOK xbrli:shares iso4217:NOK

Exhibit 31.1

 

CERTIFICATION

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Timothy Young, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of SunHydrogen, Inc. for the fiscal quarter ended December 31, 2024;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d – 15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 10, 2025

 

/s/ Timothy Young  
Timothy Young  
Chief Executive Officer & Acting Chief Financial Officer  
(Principal Executive and Financial Officer)  

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of SunHydrogen, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2024 as filed with the Securities and Exchange Commission the date hereof (the “Report”), I, Timothy Young, Chief Executive Officer & Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: February 10, 2025 /s/ Timothy Young
  Timothy Young
  Chief Executive Officer & Acting Chief Financial Officer
  (Principal Executive and Financial Officer)

 

v3.25.0.1
Cover - shares
6 Months Ended
Dec. 31, 2024
Feb. 10, 2025
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Dec. 31, 2024  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q2  
Entity Information [Line Items]    
Entity Registrant Name SUNHYDROGEN, INC.  
Entity Central Index Key 0001481028  
Entity File Number 000-54437  
Entity Tax Identification Number 26-4298300  
Entity Incorporation, State or Country Code NV  
Current Fiscal Year End Date --06-30  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Incorporation, Date of Incorporation Feb. 18, 2009  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One BioVentures Center  
Entity Address, Address Line Two 2500 Crosspark Road  
Entity Address, City or Town Coralville  
Entity Address, State or Province IA  
Entity Address, Postal Zip Code 52241  
Entity Phone Fax Numbers [Line Items]    
City Area Code (805)  
Local Phone Number 966-6566  
Entity Listings [Line Items]    
Entity Common Stock, Shares Outstanding   5,437,338,655
v3.25.0.1
Condensed Balance Sheets - USD ($)
Dec. 31, 2024
Jun. 30, 2024
CURRENT ASSETS    
Cash and cash equivalents $ 39,631,955 $ 39,044,795
Prepaid expenses 164,585
TOTAL CURRENT ASSETS 39,796,540 43,146,197
PROPERTY & EQUIPMENT    
Machinery and equipment 36,830 36,830
Computers and peripherals 11,529 11,529
Vehicle 135,260 135,260
Gross property and equipment 183,619 183,619
Less: accumulated depreciation (36,255) (20,549)
NET PROPERTY AND EQUIPMENT 147,364 163,070
INTANGIBLE ASSETS    
TOTAL INTANGIBLE ASSETS 55,209 58,549
TOTAL OTHER ASSETS 202,573 221,619
TOTAL ASSETS 39,999,113 43,367,816
CURRENT LIABILITIES    
Accounts payable and other payables 361,792 573,127
Accrued expenses 161,497 140,558
TOTAL LIABILITIES 523,289 759,514
COMMIMENTS AND CONTINGENCIES
Series C 10% Preferred Stock, 6,651 and 8,851 shares issued and outstanding, redeemable value of $665,100 and $885,100, respectively 665,100 885,100
SHAREHOLDERS’ EQUITY    
Preferred Stock, $0.001 par value; 5,000,000 authorized preferred shares
Common Stock, $0.001 par value; 10,000,000,000 authorized common shares 5,437,338,655 and 5,087,245,974 shares issued and outstanding, respectively 5,437,339 5,087,246
Additional Paid in Capital 130,743,528 128,488,199
Accumulated deficit (97,370,143) (91,852,243)
TOTAL SHAREHOLDERS’ EQUITY 38,810,724 41,723,202
TOTAL LIABILITIES, PREFERRED STOCK SUBJECT TO REDEEMPTION AND SHAREHOLDERS’ EQUITY 39,999,113 43,367,816
Related Party    
CURRENT ASSETS    
Equity securities, related party 4,101,402
CURRENT LIABILITIES    
Loan payable, related party 45,829
Trademark    
INTANGIBLE ASSETS    
Intangible assets, gross 257 315
Patents    
INTANGIBLE ASSETS    
Intangible assets, gross $ 54,952 $ 58,234
v3.25.0.1
Condensed Balance Sheets (Parentheticals) - USD ($)
Dec. 31, 2024
Jun. 30, 2024
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, share authorized 10,000,000,000 10,000,000,000
Common stock, shares issued 5,437,338,655 5,087,245,974
Common stock, shares outstanding 5,437,338,655 5,087,245,974
Series C Preferred Stock    
Preferred stock, percentage 10.00% 10.00%
Preferred stock, shares issued 6,651 8,851
Preferred stock, shares outstanding 6,651 8,851
Preferred stock, redeemable value (in Dollars) $ 665,100 $ 885,100
Trademark    
Net of amortization (in Dollars) 885 827
Patents    
Net of amortization (in Dollars) $ 46,191 $ 42,909
v3.25.0.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]        
REVENUE
OPERATING EXPENSES        
Selling and Marketing 323 647 44,000
General and administrative expenses 621,609 497,844 1,040,353 1,002,505
Research and development cost 626,318 756,263 1,234,323 1,195,327
Depreciation and amortization 9,692 10,775 19,046 21,780
TOTAL OPERATING EXPENSES 1,257,942 1,264,882 2,294,369 2,263,612
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES) (1,257,942) (1,264,882) (2,294,369) (2,263,612)
OTHER INCOME/(EXPENSES)        
Investment income 439,645 484,984 919,368 960,593
Dividend expense (39,565) (22,591) (40,871) (43,520)
Unrealized (gain)/loss on change in fair value of investment, related party (2,613,117) (2,224,504) (4,101,402) (1,938,835)
Realized gain(loss) on redemption of marketable securities (188,040)
Interest expense (83) (1,714) (626) (3,405)
TOTAL OTHER INCOME (EXPENSES) (2,213,120) (1,763,825) (3,223,531) (1,213,207)
NET INCOME (LOSS) $ (3,471,062) $ (3,028,707) $ (5,517,900) $ (3,476,819)
BASIC EARNINGS (LOSS) PER SHARE (in Dollars per share) $ 0 $ 0 $ 0 $ 0
DILUTED EARNINGS (LOSS) PER SHARE (in Dollars per share) $ 0 $ 0 $ 0 $ 0
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC (in Shares) 5,303,929,044 5,069,670,749 5,203,191,703 4,965,620,378
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING DILUTED (in Shares) 5,303,929,044 5,069,670,749 5,203,191,703 4,965,620,378
v3.25.0.1
Condensed Statements of Shareholder’s Deficit - USD ($)
Preferred Stock
Mezzanine
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Jun. 30, 2023 $ 1,095,100 $ 4,821,298 $ 126,889,423 $ (81,971,040) $ 49,739,681
Balance (in Shares) at Jun. 30, 2023   4,821,298,283      
Issuance of common stock upon partial conversion of purchase agreement for cash $ 18,684 225,291 243,975
Issuance of common stock upon partial conversion of purchase agreement for cash (in Shares)   18,684,057      
Issuance of common stock upon conversion of stock (210,000) $ 221,053 (11,053) 210,000
Issuance of common stock upon conversion of stock (in Shares)   221,052,632      
Stock compensation expense 72,481 72,481
Net Loss (448,112) (448,112)
Balance at Sep. 30, 2023 885,100 $ 5,061,035 127,176,142 (82,419,152) 49,818,025
Balance (in Shares) at Sep. 30, 2023   5,061,034,972      
Balance at Jun. 30, 2023 1,095,100 $ 4,821,298 126,889,423 (81,971,040) 49,739,681
Balance (in Shares) at Jun. 30, 2023   4,821,298,283      
Net Loss           (3,476,819)
Balance at Dec. 31, 2023 885,100 $ 5,092,815 127,509,819 (85,447,859) 47,154,775
Balance (in Shares) at Dec. 31, 2023   5,092,814,633      
Balance at Sep. 30, 2023 885,100 $ 5,061,035 127,176,142 (82,419,152) 49,818,025
Balance (in Shares) at Sep. 30, 2023   5,061,034,972      
Issuance of common stock upon partial conversion of purchase agreement for cash     $ 31,780 261,195 292,975
Issuance of common stock upon partial conversion of purchase agreement for cash (in Shares)   31,779,661      
Stock compensation expense     72,482 72,482
Net Loss   (3,028,707) (3,028,707)
Balance at Dec. 31, 2023 885,100 $ 5,092,815 127,509,819 (85,447,859) 47,154,775
Balance (in Shares) at Dec. 31, 2023   5,092,814,633      
Balance at Jun. 30, 2024 885,100 $ 5,087,246 128,488,199 (91,852,243) 41,723,202
Balance (in Shares) at Jun. 30, 2024   5,087,245,974      
Issuance of common stock upon partial conversion of purchase agreement for cash $ 118,514 2,083,411 2,201,925
Issuance of common stock upon partial conversion of purchase agreement for cash (in Shares)   118,513,734      
Stock compensation expense 9,981 9,981
Net Loss (2,046,838) (2,046,838)
Balance at Sep. 30, 2024 885,100 $ 5,205,760 130,581,591 (93,899,081) 41,888,270
Balance (in Shares) at Sep. 30, 2024   5,205,759,708      
Balance at Jun. 30, 2024 885,100 $ 5,087,246 128,488,199 (91,852,243) 41,723,202
Balance (in Shares) at Jun. 30, 2024   5,087,245,974      
Net Loss           (5,517,900)
Balance at Dec. 31, 2024 665,100 $ 5,437,339 130,743,528 (97,370,143) 38,810,724
Balance (in Shares) at Dec. 31, 2024   5,437,338,655      
Balance at Sep. 30, 2024 885,100 $ 5,205,760 130,581,591 (93,899,081) 41,888,270
Balance (in Shares) at Sep. 30, 2024   5,205,759,708      
Issuance of common stock upon conversion of stock   (220,000) $ 231,579 (11,579)   220,000
Issuance of common stock upon conversion of stock (in Shares)   231,578,947      
Stock compensation expense       173,516   173,516
Net Loss (3,471,062) (3,471,062)
Balance at Dec. 31, 2024 $ 665,100 $ 5,437,339 $ 130,743,528 $ (97,370,143) $ 38,810,724
Balance (in Shares) at Dec. 31, 2024   5,437,338,655      
v3.25.0.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net Income (Loss) $ (5,517,900) $ (3,476,819)
Adjustment to reconcile net income (loss) to net cash (used in) provided by operating activities    
Depreciation & amortization expense 19,046 21,780
Stock based compensation expense for services 183,497 144,963
Loss on redemption of marketable securities 188,040
Unrealized (gain)/loss on change in fair value of investment, related party 4,101,402 1,938,835
Change in assets and liabilities :    
Interest receivable on certificate of deposit (61,200)
Prepaid expense (164,585)
Accounts payable (211,335) 236,392
Accrued expenses 20,939 59,057
NET CASH USED IN OPERATING ACTIVITIES (1,568,936) (948,952)
CASH FLOWS FROM INVESTING ACTIVITIES    
Marketable securities purchased (168,733,113)
Marketable securities redeemed 164,145,423
Purchase of certificate of deposit (5,000,000)
Purchase of marketable securities unsettled 4,587,690
Redemption of short term investments in corporate securities 3,000,000
NET CASH USED IN INVESTING ACTIVITIES (2,000,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of related party note payable (45,829) (52,333)
Net proceeds from common stock purchase agreements 2,201,925 536,950
NET CASH PROVIDED BY FINANCING ACTIVITIES 2,156,096 484,617
Net increase (decrease) in cash and cash equivalents 587,160 (2,464,335)
Cash and cash equivalents - beginning of period 39,044,795 37,185,989
Cash and cash equivalents - end of period 39,631,955 34,721,654
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION    
Interest paid 626 3,406
Taxes paid
SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS    
Conversion of Series C Preferred shares to common stock $ 220,000 $ 210,000
v3.25.0.1
Organization and Line of Business
6 Months Ended
Dec. 31, 2024
Organization and Line of Business [Abstract]  
ORGANIZATION AND LINE OF BUSINESS
1.ORGANIZATION AND LINE OF BUSINESS

 

Organization

 

SunHydrogen, Inc. (the “Company”) was incorporated in the state of Nevada on February 18, 2009. The Company, based in Coralville, IA began operations on February 19, 2009.

 

Line of Business

 

The company is currently developing a novel solar-powered nanoparticle system that mimics photosynthesis to separate hydrogen from water. We intend for technology of this system to be used for the production of renewable hydrogen to produce renewable electricity and hydrogen for fuel cells and other applications where hydrogen is used.

 

SunHydrogen is developing an efficient and cost-effective way to produce green hydrogen using sunlight and any source of water. Just like a solar panel is comprised of multiple cells that generate electricity, our hydrogen panel encases multiple hydrogen generators immersed in water. Each hydrogen generator contains billions of electroplated nanoparticles, autonomously splitting water into hydrogen and oxygen. We believe our technology has the potential to be one of – if not the most – economical green hydrogen solutions: Unlike traditional water electrolysis for hydrogen, our process requires no external power other than sunlight and uses efficient and low-cost materials.

v3.25.0.1
Summary of Significant Accounting Policies
6 Months Ended
Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2024 are not necessarily indicative of the results that may be expected for the year ended June 30, 2025. For further information refer to the financial statements and footnotes thereto included in the Company’s Form 10-K for the year ended June 30, 2024.

 

Cash and Cash Equivalent

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

The following table provides detail of our cash and cash equivalents.

 

   December 31,
2024
    

June 30,
2024

 
Cash  $29,630,222   $29,365,997 
U.S. Treasury bills   10,001,733    9,678,798 
Total cash and cash equivalents  $39,631,955   $39,044,795 

 

The U.S. Treasury bills have a credit quality indicator of AA/A.

 

Concentration risk

 

Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Company (FDIC) limits. At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of the FDIC limits. As of December 31, 2024, the cash balance in excess of the FDIC limits was $37,834,640. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.

 

Use of Estimates

 

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, fair value of financial instruments, and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

 

Property and Equipment

 

Property and equipment are stated at cost and are depreciated using straight line over their estimated useful lives.

 

Computers and peripheral equipment   5 Years 
Vehicle   5 Years 

 

The Company recognized depreciation expense of $15,706 and $18,411 for the six months ended December 31, 2024 and 2023, respectively. 

 

Intangible Assets

 

The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives.

 

    Useful Lives   December 31,
2024
     June 30,
2024
 
                 
Trademark-gross   10 years   $ 1,142     $ 1,142  
Less accumulated amortization         (885 )     (827 )
Trademark-net       $ 257     $ 315  
                     
Patents-gross   15 years   $ 101,143     $ 101,143  
Less accumulated amortization         (46,191 )     (42,909 )
Patents-net       $ 54,952     $ 58,234  

 

The Company recognized amortization expense of $3,340 and $3,369 for the six months ended December 31, 2024 and 2023, respectively.

 

Future Amortization Expense

 

Year  Amount 
2025 (remaining)  $3,340 
2026   6,622 
2027   6,622 
2028   6,650 
2029   6,565 
Thereafter   25,410 
   $55,209 

 

Impairment of Long-lived Assets

 

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

 

When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended December 31, 2024 and 2023, the Company determined no impairment was required.

 

Net Earnings (Loss) per Share Calculations

 

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the three and six months ended December 31, 2024 and 2023. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards, if dilutive. 

 

The total potential common shares as of December 31, 2024, include 255,465,911 stock options, 78,095,239 common stock purchase warrants, and 700,105,263 common shares issuable upon conversion of the outstanding 6,651 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is antidilutive. 

 

The total potential common shares as of December 31, 2023, include 218,394,499 stock options, 86,495,239 common stock purchase warrants, and 931,684,211 common shares issuable upon conversion of the outstanding 8,851 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is antidilutive.

 

Stock Based Compensation

 

The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.

 

Warrant Accounting 

 

The Company accounts for warrants to purchase shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation model.

 

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate that value. As of December 31, 2024, the amounts reported for cash, accounts payable and other payables, and accrued expenses approximate the fair value because of their short maturities.

 

We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

 

These tiers include:

 

  Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.

 

  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active.

 

  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows (See Note 7):

 

December 31, 2024

 

    Total    (Level 1)    (Level 2)    (Level 3) 
Assets:                    
Equity securities, related party  $
-
   $
-
   $
-
   $
-
 
   $
-
   $
-
   $
-
   $
-
 

 

June 30, 2024

 

   Total   (Level 1)   (Level 2)   (Level 3) 
Assets:                
Equity securities, related party  $4,101,402   $
       -
   $4,101,402   $
        -
 
   $4,101,402   $
-
   $4,101,402   $
-
 

 

As of December 31, 2024, the Equity securities, related party had a fair value of $0 which was measured using a level 3 input due to the underlying securities no longer trading on an active stock exchange (See Note 7).

 

Research and Development

 

Research and development costs are expensed as incurred.  Total research and development costs were $1,234,323 and $1,195,327 for the six months ended December 31, 2024 and 2023, respectively.

 

Advertising and Marketing

 

Advertising and marketing cost are expensed as incurred. Total advertising and marketing costs were $647 and $44,000 for the six months ended December 31, 2024 and 2023, respectively.

 

Accounting for Derivatives

 

The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates.

 

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

 

Recently Issued Accounting Pronouncements

 

Management believes that no recently issued accounting standards, which are not yet effective, would have a material impact on the accompanying unaudited financial statements as of December 31, 2024, if adopted at this time.

 

Reclassification

 

Certain accounts from prior periods have been reclassified to conform to the current period presentation.

v3.25.0.1
Preferred Stock
6 Months Ended
Dec. 31, 2024
Preferred Stock [Abstract]  
PREFERRED STOCK
3.PREFERRED STOCK

 

Series C Preferred Stock

 

On December 15, 2021, the Company filed a certificate of designation of Series C Preferred Stock with the Secretary of State of Nevada, designating 17,000 shares of preferred stock as Series C Preferred Stock. Each share of Series C Preferred Stock has a stated value of $100 and is convertible into shares of common stock of the Company at a conversion price of $0.00095. The Series C Preferred Stock holders are entitled to receive out of any funds and assets of the Company legally available prior and in preference to any declaration or payment of any dividend on the common stock of the Company, cumulative dividends, at an annual rate of 10% of the stated value, payable in cash or shares of common stock. In the event the Company declares or pays a dividend on its shares of common stock (other than dividend payable in shares of common stock), the holders of Series C Preferred Stock will also be entitled to receive payment of such dividend on an as--converted basis. The Series C Preferred Stock confers no voting rights on holders, except with respect to matters that materially and adversely affect the voting powers, rights or preferences of the Series C Preferred Stock or as otherwise required by applicable law. Upon liquidation, dissolution and winding up of the Company, the holders of Series C Preferred Stock will be entitled to receive, before any payments will made or any assets distributed to the holders of the common stock, the stated value of the Series C Preferred Shares plus any declared but unpaid dividends. No other current or future equity holders of the Company will have higher priority of liquidation preference than holders of Series C Preferred Stock.

 

The Series C Preferred Stock is presented as mezzanine equity because it is redeemable at a fixed or determinable amount upon an event that is outside of the Company’s control.

 

During the six months ended December 31, 2024, an investor converted 2,200 preferred shares with a stated value of $220,000, at a conversion price of $0.00095, into 231,578,947 common shares. No gain or loss was recognized in the financial statements.

 

During the six months ended December 31, 2023, an investor converted 2,100 preferred shares with a stated value of $210,000, at a conversion price of $0.00095, into 221,052,632 common shares. No gain or loss was recognized in the financial statements.

 

As of December 31, 2024 and June 30, 2024, the Company had 6,651 and 8,851 shares of Series C Preferred Stock outstanding, respectively. The fair value of the outstanding shares was $665,100 and $885,100, respectively. 

v3.25.0.1
Common Stock
6 Months Ended
Dec. 31, 2024
Common Stock [Abstract]  
COMMON STOCK
4.COMMON STOCK

 

Six Months Ended December 31, 2024

 

On November 11, 2022, the Company entered into a Purchase Agreement with an investor for the sale of up to $45,000,000 of shares of common stock. For the six months ended December 31, 2024, the Company issued 118,513,734 shares of common stock for $2,250,000 under the purchase agreement at prices of $0.0156 - $0.02024, pursuant to purchase notices received from the investor. The finance cost of $48,075 was deducted from the gross proceeds received, leaving net proceeds of $2,201,925.

 

On November 22, 2024, the Company issued 231,578,947 shares of common stock, upon conversion of 2,200 shares of preferred stock with a stated value of $220,000 at a conversion price of $0.00095.

 

Six Months Ended December 31, 2023

 

On November 11, 2022, the Company entered into a Purchase Agreement with an investor for the sale of up to $45,000,000 of common stock. For the six months ended December 31, 2023, the Company issued 50,463,718 shares of common stock for $550,000 under the purchase agreement at prices of $0.0094 - $0.0134, pursuant to purchase notices received from the investor. The finance cost of $13,050 was deducted from the gross proceeds received, leaving gross proceeds of $536,950.

 

On September 8, 2023, the Company issued 221,052,632 shares of common stock, upon conversion of 2,100 shares of preferred stock with a stated value of $210,000 at a conversion price of $0.00095. 

v3.25.0.1
Stock Incentive Plans
6 Months Ended
Dec. 31, 2024
Stock Incentive Plans [Abstract]  
STOCK INCENTIVE PLANS
5.STOCK INCENTIVE PLANS

 

2019 Equity Stock Incentive Plan

 

On December 17, 2018, the Board of Directors approved and adopted the 2019 Equity Incentive Plan (“the 2019 Plan”), with 300,000,000 shares reserved for issuance. The purpose of the 2019 Plan is to promote the success of the Company and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain, and reward selected employees and other eligible persons. The awards are performance-based compensation that are granted under the 2019 Plan as incentive stock options (ISO) or nonqualified stock options. The per share exercise price for each option shall not be less than 100% of the fair market value of a share of common stock on the date of grant of the option. The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing cost.

 

As of December 31, 2024, under the 2019 Equity Incentive Plan, there were 285,270,561 stock options and shares issued, with 14,729,439 shares remaining available for issuance.

 

2022 Equity Stock Incentive Plan

 

On January 27, 2022, the Company adopted the 2022 Equity Incentive Plan, to enable the Company to attract and retain the types of employees, consultants, and directors who will contribute to the Company’s long-range success. The maximum number of shares of common stock that may be issued under the 2022 Plan is initially 400,000,000. The number of shares will automatically be increased on the first day of the Company’s fiscal year beginning in 2023 so that the total number of shares issuable equals fifteen percent (15%) of the Company’s fully diluted capitalization on the first day of the Company’s fiscal year, unless the Board adopts a resolution providing that the number of shares issuable under the 2022 Plan shall not be so increased.

 

As of July 1, 2024, the maximum number of shares issuable under the 2022 Equity Incentive Plan was increased to 953,548,700 shares, based on the Company’s fully diluted capitalization of 6,356,991,335. As of December 31, 2024, there were 448,600,000 stock options and shares issued, with 504,948,700 shares remaining available for issuance.

v3.25.0.1
Stock Options and Warrants
6 Months Ended
Dec. 31, 2024
Stock Options and Warrants [Abstract]  
STOCK OPTIONS AND WARRANTS
6.STOCK OPTIONS AND WARRANTS

 

Options

 

Transactions involving our options are summarized as follows:

 

           Weighted 
       Weighted   Average 
       Average   Grant-Date 
   Number of   Exercise   Per Share 
   Options   Price   Fair Value 
Options outstanding at June 30, 2024   266,894,499   $0.011   $0.011 
Granted   275,000,000   $0.017   $0.013 
Canceled/Expired   (6,928,588)  $0.010   $0.010 
Exercised   
-
   $
-
   $- 
Options outstanding at December 31, 2024   534,965,911   $0.0139   $0.012 

 

Details of our options outstanding as of December 31, 2024, is as follows:

 

Options Exercisable   Weighted Average
Exercise Price of
Options Exercisable
   Weighted Average
Contractual Life of
Options Exercisable
(Years)
   Weighted Average
Contractual Life of
Options Outstanding
(Years)
 
 255,465,911    0.011    2.15    4.85 

  

Total stock compensation expense related to the options for the six months ended December, 2024 and 2023, was $183,497 and $144,963, respectively. As of December 31, 2024 there was approximately $3.5 million of unrecognized compensation cost related to the Options, which is expected to be recognized over a remaining weighted-average vesting period of approximately 1.41 years.

 

Warrants

 

Transactions involving our warrants are summarized as follows:

 

       Weighted 
   Number of
Shares
   Average
Exercise Price
 
Warrants outstanding at June 30, 2024   78,095,239   $0.121 
Issued   
-
   $
-
 
Canceled/Expired   
-
   $
-
 
Exercised   
-
   $
-
 
Warrants outstanding at December 31, 2024   78,095,239   $0.121 

 

Details of our warrants outstanding as of December 31, 2024, is as follows:

 

Warrants Exercisable   Weighted Average Contractual Life of Warrants
Outstanding and Exercisable (Years)
 
 78,095,239    1.17 
v3.25.0.1
Equity Securities, Related Party
6 Months Ended
Dec. 31, 2024
Equity Securities, Related Party [Abstract]  
EQUITY SECURITIES, RELATED PARTY

7. EQUITY SECURITIES, RELATED PARTY

 

On November 11, 2022, the Company entered into a subscription agreement with TECO 2030 ASA (“TECO”). TECO was a Norwegian based clean tech company developing zero-emission technology for the maritime and heavy industry. They were developing PEM hydrogen fuel cell stacks and PEM hydrogen fuel cell modules, that enable ships and other heavy-duty applications to become emissions-free. TECO was listed on Euronext Growth on Oslo Stock Exchange under the ticker TECO. Pursuant to the subscription agreement, the Company purchased 13,443,875 shares of TECO stock for an aggregate consideration of $7 million in USD, at an exchange rate of NOK 10.4094. The shares purchased are adjusted to fair value based on unrealized gain or loss at the end of each period. At the time of this transaction, the Company and TECO became related parties due to the Company owning an 8.3% interest in TECO. Subsequent to the equity purchase, Timothy Young, CEO of the Company, was elected to the board of TECO in January of 2023.

 

Also, on November 11, 2022 the Company purchased a bond receivable of TECO for a subscription amount of $3 million. The issuance of the bond receivable was through a Tap Issue Addendum to TECO’s secured convertible notes agreement dated June 1, 2022, pursuant to which Nordic Trustee AS was acting as the security agent on behalf of the note holders. The bond receivable would have matured on June 1, 2025, and would have been converted into shares at a rate of NOK 5.0868 per share. The note bore interest at the rate of 8% per annum, which was paid quarterly in arrears. For the six months ended December 31, 2023, the Company recognized interest income of $114,652.

 

In April of 2024, all investors of TECO bonds received an option to convert their bonds to receive one share for every two NOK. On May 24, 2024 the Company agreed to the terms and conversion, and agreed to receive 15,884,744 shares of TECO stock in exchange for the convertible bond receivable of $3,000,000 and unpaid interest. The bond receivable had a principal amount of NOK 31,228,200, and accrued and unpaid interest up to May 24, 2024 of NOK 541,289, for a total of NOK 31,769,489. The value of the shares converted on May 24, 2024 was $3,139,302 with contributed capital gain on conversion of convertible bond of $85,815 and interest received of $53,487.

 

On September 10, 2024, after a delay to allow time for legal review and clarification of the investment statements, the bond was returned. Upon receipt of the 15,884,744 shares, the Company owned a total of 29,328,619 shares, which as of September 30, 2024 represented approximately 13.29% of the outstanding shares of TECO.

 

The CEO of the Company elected to not seek reelection to the board of directors at the annual general meeting in June and is no longer a director of TECO after June 19, 2024. The CEO of the Company never received compensation of any kind for his role as director from January of 2023 through June 19, 2024.

 

During December 2024, it came to the Company’s attention that TECO filed for bankruptcy and their shares were suspended from trading on the Euronext Growth on Oslo Stock Exchange. In January 2025, TECO was delisted. Based on these events, the Company determined the fair value of their shares was $0 as of December 31, 2024.

 

On December 17, 2024, the Company entered a share allocation agreement with TECO HOLDING AS, in which Bacchus AS (“Newco” and a wholly owned subsidiary of TECO HOLDINGS AS) intends to acquire the shares and other assets owned by TECO 2030 ASA. TECO HOLDINGS AS then agreed to transfer shares in Newco equal to 13.32% of the total shares of Newco to the Company free of charge, encumbrances, and other liens. Concurrently with the transfer of shares under the allocation agreement, a representative of the Company shall, whenever preferred, be appointed to the board of directors of Newco. As of December 31, 2024, due to Newco recently being formed and there being no readily determinable fair value, the Company determined the fair value of the Newco shares was $0.

 

The following table summarizes our equity investments in TECO:

 

Date of Investment  Number of
Shares
   Cost Basis   Fair Value
as of
June 30,
2024
   Unrealized Loss   Fair Value
as of
December 31,
2024
 
November 24, 2022   13,443,875   $7,000,000   $1,880,032   $(1,880,032)  $
-
 
May 24, 2024   15,884,744    3,139,302    2,221,370    (2,221,370)   
-
 
Total   29,328,619   $10,139,302   $4,101,402   $(4,101,402)  $
-
 
v3.25.0.1
Investment Income
6 Months Ended
Dec. 31, 2024
Investment Income [Abstract]  
INVESTMENT INCOME
8.INVESTMENT INCOME

 

The following table summarizes our investment income.

 

   December 31,
2024
   December 31,
2023
 
Interest earned on cash (NOTE 2)  $675,207   $52,468 
Interest earned on Treasury Bills (NOTE 2)   240,475    664,157 
Interest earned on Certificates of Deposit (NOTE 9)   
-
    61,200 
Interest earned on Corporate Bonds   
-
    54,375 
Interest earned on TECO bond (NOTE 7)   
-
    114,652 
Dividends and other   3,686    13,741 
Total investment income  $919,368   $960,593 
v3.25.0.1
Short Term Investments
6 Months Ended
Dec. 31, 2024
Short Term Investments [Abstract]  
SHORT TERM INVESTMENTS
9.SHORT TERM INVESTMENTS

 

On September 12, 2023, the Company invested in a $5,000,000 certificate of deposit (CD), which matured on March 12, 2024. CDs should be reported as part of cash and cash equivalents at cost plus accrued interest if less than 90 days from the purchase date, and on its own line in the financial statements if the purchase is greater than 90 days. The CD has been classified as a short-term investment due to the length of time to maturity at acquisition and was measured using Level 2. The CD was reinvested upon maturity. The Company recognized interest income of $61,200 which was reported in the Company’s financial statements as of December 31, 2023.

v3.25.0.1
Commitments and Contingencies
6 Months Ended
Dec. 31, 2024
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES
10.COMMITMENTS AND CONTINGENCIES

 

Effective October 1, 2024, the Company extended its research agreement with the University of Iowa through September 30, 2025. As consideration under the research agreement, the University of Iowa will receive a maximum of $302,459 from the Company in four equal installments of $75,615. The agreement can be terminated by either party upon sixty (60) days prior written notice to the other. As of December 31, 2024, there is a balance due of $75,615 per the agreement.

 

Effective October 1, 2024, the Company extended its research agreement with the University of Michigan through September 30, 2025. As consideration under the research agreement, the University of Michigan will receive a maximum of $252,246 from the Company. In the event of early termination by the Sponsor, the Sponsor will pay all costs accrued by the University as of the date of termination, including non-cancellable obligations. As of December 31, 2024, there is a balance due of $63,062 per the agreement and $40,091 per the prior amended research agreement for a total of $103,153.

 

The Company began renting lab space in February 2022. The lab rental is on a month-to-month basis and is cancellable with a thirty (30) day notice. On April 1, 2024, the Company renewed the space needed for its lab work at a monthly rent of $6,400 per month. Due to the rental being month-to-month, ASC 842 lease accounting is not applicable.

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s financial position or results of operation.

v3.25.0.1
Related Party
6 Months Ended
Dec. 31, 2024
Related Party [Abstract]  
RELATED PARTY
11.RELATED PARTY

 

Shareholders Loan

 

During the period ended December 31, 2022, the Company entered into a $211,750 loan with the Company’s CEO for the repayment of accrued salary expense. The loan bore interest of five percent (5%) and was to be repaid with monthly payments of $9,290, including interest and principal over a two-year period. As of December 31, 2024 and June 30, 2024, the principal balance remaining on the loan was $0 and $45,829, respectively and interest paid during the six months ended December 31, 2024 and 2023 was $620 and $3,405, respectively.

 

Other Related Party Activity

 

See Note 7 for related party transactions with respect to TECO 2030 A.S.A. and Newco.

v3.25.0.1
Subsequent Events
6 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
12.SUBSEQUENT EVENTS

 

Management evaluated subsequent events as of the date of the financial statements pursuant to ASC TOPIC 855 and had the following subsequent events to report.

v3.25.0.1
Pay vs Performance Disclosure - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure            
Net Income (Loss) $ (3,471,062) $ (2,046,838) $ (3,028,707) $ (448,112) $ (5,517,900) $ (3,476,819)
v3.25.0.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.0.1
Accounting Policies, by Policy (Policies)
6 Months Ended
Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2024 are not necessarily indicative of the results that may be expected for the year ended June 30, 2025. For further information refer to the financial statements and footnotes thereto included in the Company’s Form 10-K for the year ended June 30, 2024.

Cash and Cash Equivalent

Cash and Cash Equivalent

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

The following table provides detail of our cash and cash equivalents.

   December 31,
2024
    

June 30,
2024

 
Cash  $29,630,222   $29,365,997 
U.S. Treasury bills   10,001,733    9,678,798 
Total cash and cash equivalents  $39,631,955   $39,044,795 

The U.S. Treasury bills have a credit quality indicator of AA/A.

 

Concentration risk

Concentration risk

Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Company (FDIC) limits. At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of the FDIC limits. As of December 31, 2024, the cash balance in excess of the FDIC limits was $37,834,640. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.

Use of Estimates

Use of Estimates

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, fair value of financial instruments, and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost and are depreciated using straight line over their estimated useful lives.

Computers and peripheral equipment   5 Years 
Vehicle   5 Years 

The Company recognized depreciation expense of $15,706 and $18,411 for the six months ended December 31, 2024 and 2023, respectively. 

Intangible Assets

Intangible Assets

The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives.

    Useful Lives   December 31,
2024
     June 30,
2024
 
                 
Trademark-gross   10 years   $ 1,142     $ 1,142  
Less accumulated amortization         (885 )     (827 )
Trademark-net       $ 257     $ 315  
                     
Patents-gross   15 years   $ 101,143     $ 101,143  
Less accumulated amortization         (46,191 )     (42,909 )
Patents-net       $ 54,952     $ 58,234  

The Company recognized amortization expense of $3,340 and $3,369 for the six months ended December 31, 2024 and 2023, respectively.

Future Amortization Expense

Year  Amount 
2025 (remaining)  $3,340 
2026   6,622 
2027   6,622 
2028   6,650 
2029   6,565 
Thereafter   25,410 
   $55,209 

 

Impairment of Long-lived Assets

Impairment of Long-lived Assets

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended December 31, 2024 and 2023, the Company determined no impairment was required.

Net Earnings (Loss) per Share Calculations

Net Earnings (Loss) per Share Calculations

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the three and six months ended December 31, 2024 and 2023. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards, if dilutive. 

The total potential common shares as of December 31, 2024, include 255,465,911 stock options, 78,095,239 common stock purchase warrants, and 700,105,263 common shares issuable upon conversion of the outstanding 6,651 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is antidilutive. 

The total potential common shares as of December 31, 2023, include 218,394,499 stock options, 86,495,239 common stock purchase warrants, and 931,684,211 common shares issuable upon conversion of the outstanding 8,851 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is antidilutive.

Stock Based Compensation

Stock Based Compensation

The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.

Warrant Accounting

Warrant Accounting 

The Company accounts for warrants to purchase shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation model.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate that value. As of December 31, 2024, the amounts reported for cash, accounts payable and other payables, and accrued expenses approximate the fair value because of their short maturities.

We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

These tiers include:

  Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.
  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active.
  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows (See Note 7):

December 31, 2024

    Total    (Level 1)    (Level 2)    (Level 3) 
Assets:                    
Equity securities, related party  $
-
   $
-
   $
-
   $
-
 
   $
-
   $
-
   $
-
   $
-
 

June 30, 2024

   Total   (Level 1)   (Level 2)   (Level 3) 
Assets:                
Equity securities, related party  $4,101,402   $
       -
   $4,101,402   $
        -
 
   $4,101,402   $
-
   $4,101,402   $
-
 

As of December 31, 2024, the Equity securities, related party had a fair value of $0 which was measured using a level 3 input due to the underlying securities no longer trading on an active stock exchange (See Note 7).

Research and Development

Research and Development

Research and development costs are expensed as incurred.  Total research and development costs were $1,234,323 and $1,195,327 for the six months ended December 31, 2024 and 2023, respectively.

Advertising and Marketing

Advertising and Marketing

Advertising and marketing cost are expensed as incurred. Total advertising and marketing costs were $647 and $44,000 for the six months ended December 31, 2024 and 2023, respectively.

 

Accounting for Derivatives

Accounting for Derivatives

The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Management believes that no recently issued accounting standards, which are not yet effective, would have a material impact on the accompanying unaudited financial statements as of December 31, 2024, if adopted at this time.

Reclassification

Reclassification

Certain accounts from prior periods have been reclassified to conform to the current period presentation.

v3.25.0.1
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents The following table provides detail of our cash and cash equivalents.
   December 31,
2024
    

June 30,
2024

 
Cash  $29,630,222   $29,365,997 
U.S. Treasury bills   10,001,733    9,678,798 
Total cash and cash equivalents  $39,631,955   $39,044,795 
Schedule of Property and Equipment are Stated at Cost and are Depreciated Using Straight Line Over its Estimated Useful Lives Property and equipment are stated at cost and are depreciated using straight line over their estimated useful lives.
Computers and peripheral equipment   5 Years 
Vehicle   5 Years 
Schedule of Intangible Assets that Have Finite Useful Lives Intangible assets that have finite useful lives continue to be amortized over their useful lives.
    Useful Lives   December 31,
2024
     June 30,
2024
 
                 
Trademark-gross   10 years   $ 1,142     $ 1,142  
Less accumulated amortization         (885 )     (827 )
Trademark-net       $ 257     $ 315  
                     
Patents-gross   15 years   $ 101,143     $ 101,143  
Less accumulated amortization         (46,191 )     (42,909 )
Patents-net       $ 54,952     $ 58,234  
Schedule of Future Amortization Expense of Intangible Assets Future Amortization Expense
Year  Amount 
2025 (remaining)  $3,340 
2026   6,622 
2027   6,622 
2028   6,650 
2029   6,565 
Thereafter   25,410 
   $55,209 

 

Schedule of Cash and Cash Equivalents Assets and liabilities measured at fair value on a recurring basis are as follows (See Note 7):
    Total    (Level 1)    (Level 2)    (Level 3) 
Assets:                    
Equity securities, related party  $
-
   $
-
   $
-
   $
-
 
   $
-
   $
-
   $
-
   $
-
 
   Total   (Level 1)   (Level 2)   (Level 3) 
Assets:                
Equity securities, related party  $4,101,402   $
       -
   $4,101,402   $
        -
 
   $4,101,402   $
-
   $4,101,402   $
-
 
v3.25.0.1
Stock Options and Warrants (Tables)
6 Months Ended
Dec. 31, 2024
Stock Options and Warrants [Line Items]  
Schedule of Stock Option Transactions Transactions involving our options are summarized as follows:
           Weighted 
       Weighted   Average 
       Average   Grant-Date 
   Number of   Exercise   Per Share 
   Options   Price   Fair Value 
Options outstanding at June 30, 2024   266,894,499   $0.011   $0.011 
Granted   275,000,000   $0.017   $0.013 
Canceled/Expired   (6,928,588)  $0.010   $0.010 
Exercised   
-
   $
-
   $- 
Options outstanding at December 31, 2024   534,965,911   $0.0139   $0.012 
Schedule of Options Outstanding Details of our options outstanding as of December 31, 2024, is as follows:
Options Exercisable   Weighted Average
Exercise Price of
Options Exercisable
   Weighted Average
Contractual Life of
Options Exercisable
(Years)
   Weighted Average
Contractual Life of
Options Outstanding
(Years)
 
 255,465,911    0.011    2.15    4.85 
Schedule of Stock Option Transactions Transactions involving our warrants are summarized as follows:
       Weighted 
   Number of
Shares
   Average
Exercise Price
 
Warrants outstanding at June 30, 2024   78,095,239   $0.121 
Issued   
-
   $
-
 
Canceled/Expired   
-
   $
-
 
Exercised   
-
   $
-
 
Warrants outstanding at December 31, 2024   78,095,239   $0.121 
Warrant [Member]  
Stock Options and Warrants [Line Items]  
Schedule of Options Outstanding Details of our warrants outstanding as of December 31, 2024, is as follows:
Warrants Exercisable   Weighted Average Contractual Life of Warrants
Outstanding and Exercisable (Years)
 
 78,095,239    1.17 
v3.25.0.1
Equity Securities, Related Party (Tables)
6 Months Ended
Dec. 31, 2024
Equity Securities, Related Party [Abstract]  
Schedule of Summarizes our Equity Investments in TECO The following table summarizes our equity investments in TECO:
Date of Investment  Number of
Shares
   Cost Basis   Fair Value
as of
June 30,
2024
   Unrealized Loss   Fair Value
as of
December 31,
2024
 
November 24, 2022   13,443,875   $7,000,000   $1,880,032   $(1,880,032)  $
-
 
May 24, 2024   15,884,744    3,139,302    2,221,370    (2,221,370)   
-
 
Total   29,328,619   $10,139,302   $4,101,402   $(4,101,402)  $
-
 
v3.25.0.1
Investment Income (Tables)
6 Months Ended
Dec. 31, 2024
Investment Income [Abstract]  
Schedule of Investment Income The following table summarizes our investment income.
   December 31,
2024
   December 31,
2023
 
Interest earned on cash (NOTE 2)  $675,207   $52,468 
Interest earned on Treasury Bills (NOTE 2)   240,475    664,157 
Interest earned on Certificates of Deposit (NOTE 9)   
-
    61,200 
Interest earned on Corporate Bonds   
-
    54,375 
Interest earned on TECO bond (NOTE 7)   
-
    114,652 
Dividends and other   3,686    13,741 
Total investment income  $919,368   $960,593 
v3.25.0.1
Organization and Line of Business (Details)
6 Months Ended
Dec. 31, 2024
Organization and Line of Business [Abstract]  
Date of Incorporation Feb. 18, 2009
v3.25.0.1
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Jun. 30, 2024
Summary of Significant Accounting Policies [Line Items]          
Federal deposit insurance company     $ 37,834,640    
Depreciation expense     15,706 $ 18,411  
Amortization expense     3,340 3,369  
Equity securities fair value     $ 4,101,402
Total research and development costs 626,318 $ 756,263 1,234,323 1,195,327  
Total advertising and marketing costs     647 $ 44,000  
Level 3 [Member]          
Summary of Significant Accounting Policies [Line Items]          
Equity securities fair value    
Related Party [Member] | Level 3 [Member]          
Summary of Significant Accounting Policies [Line Items]          
Equity securities fair value $ 0   $ 0    
Stock Options [Member]          
Summary of Significant Accounting Policies [Line Items]          
Total potential common shares (in Shares)     255,465,911 218,394,499  
Common Stock Purchase Warrants [Member]          
Summary of Significant Accounting Policies [Line Items]          
Total potential common shares (in Shares)     78,095,239 86,495,239  
Common Stock [Member]          
Summary of Significant Accounting Policies [Line Items]          
Total potential common shares (in Shares)     700,105,263 931,684,211  
Series C Preferred Shares [Member]          
Summary of Significant Accounting Policies [Line Items]          
Total potential common shares (in Shares)     6,651 8,851  
v3.25.0.1
Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents (Details) - USD ($)
Dec. 31, 2024
Jun. 30, 2024
Schedule of Cash and Cash Equivalents [Line Items]    
Total cash and cash equivalents $ 39,631,955 $ 39,044,795
Cash [Member]    
Schedule of Cash and Cash Equivalents [Line Items]    
Total cash and cash equivalents 29,630,222 29,365,997
U.S. Treasury bills [Member]    
Schedule of Cash and Cash Equivalents [Line Items]    
Total cash and cash equivalents $ 10,001,733 $ 9,678,798
v3.25.0.1
Summary of Significant Accounting Policies - Schedule of Property and Equipment are Stated at Cost and are Depreciated Using Straight Line Over its Estimated Useful Lives (Details)
Dec. 31, 2024
Computers and peripheral equipment [Member]  
Schedule of Property and Equipment are Stated at Cost and are Depreciated Using Straight Line Over its Estimated Useful Lives [Line Items]  
Estimated useful lives 5 years
Vehicle [Member]  
Schedule of Property and Equipment are Stated at Cost and are Depreciated Using Straight Line Over its Estimated Useful Lives [Line Items]  
Estimated useful lives 5 years
v3.25.0.1
Summary of Significant Accounting Policies - Schedule of Intangible Assets that have Finite Useful Lives (Details) - USD ($)
Dec. 31, 2024
Jun. 30, 2024
Trademark [Member]    
Schedule of Intangible Assets that Have Finite Useful Lives [Line Items]    
Useful Lives 10 years  
Intangible assets - gross $ 1,142 $ 1,142
Less accumulated amortization (885) (827)
Intangible assets - net $ 257 315
Patents [Member]    
Schedule of Intangible Assets that Have Finite Useful Lives [Line Items]    
Useful Lives 15 years  
Intangible assets - gross $ 101,143 101,143
Less accumulated amortization (46,191) (42,909)
Intangible assets - net $ 54,952 $ 58,234
v3.25.0.1
Summary of Significant Accounting Policies - Schedule of Future Amortization Expense of Intangible Assets (Details) - USD ($)
Dec. 31, 2024
Jun. 30, 2024
Schedule of Future Amortization Expense of Intangible Assets [Abstract]    
2025 (remaining) $ 3,340  
2026 6,622  
2027 6,622  
2028 6,650  
2029 6,565  
Thereafter 25,410  
TOTAL INTANGIBLE ASSETS $ 55,209 $ 58,549
v3.25.0.1
Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
Dec. 31, 2024
Jun. 30, 2024
Assets:    
Equity securities, related party $ 4,101,402
Total 4,101,402
Level 1 [Member]    
Assets:    
Equity securities, related party
Total
Level 2 [Member]    
Assets:    
Equity securities, related party 4,101,402
Total 4,101,402
Level 3 [Member]    
Assets:    
Equity securities, related party
Total
v3.25.0.1
Preferred Stock (Details) - USD ($)
6 Months Ended
Dec. 15, 2021
Dec. 31, 2024
Dec. 31, 2023
Jun. 30, 2024
Preferred Stock [Line Items]        
Conversion price per share (in Dollars per share)   $ 0.00095 $ 0.00095  
Conversion price (in Dollars)   $ 220,000 $ 210,000  
Series C Preferred Stock [Member]        
Preferred Stock [Line Items]        
Preferred stock designated shares 17,000      
Preferred stock stated value (in Dollars) $ 100      
Conversion price per share (in Dollars per share) $ 0.00095      
Dividend percentage 10.00%      
Number of shares converted     2,100  
Preferred stock, shares outstanding   6,651   8,851
Preferred stock, redeemable value (in Dollars)   $ 665,100   $ 885,100
Preferred Stock [Member]        
Preferred Stock [Line Items]        
Number of shares converted   2,200    
Common Stock [Member]        
Preferred Stock [Line Items]        
Converted preferred shares   231,578,947 221,052,632  
v3.25.0.1
Common Stock (Details) - USD ($)
6 Months Ended
Nov. 22, 2024
Sep. 08, 2023
Nov. 11, 2022
Dec. 31, 2024
Dec. 31, 2023
Common Stock [Line Items]          
Net proceeds       $ 2,201,925 $ 536,950
Conversion price (in Dollars per share)       $ 0.00095 $ 0.00095
Purchase Agreement [Member]          
Common Stock [Line Items]          
Finance cost       $ 48,075  
Purchase Agreement with an Investor [Member]          
Common Stock [Line Items]          
Finance cost         $ 13,050
Minimum [Member] | Purchase Agreement with an Investor [Member]          
Common Stock [Line Items]          
Price per share (in Dollars per share)         $ 0.0094
Maximum [Member] | Purchase Agreement with an Investor [Member]          
Common Stock [Line Items]          
Price per share (in Dollars per share)         $ 0.0134
Common Stock [Member]          
Common Stock [Line Items]          
Sale of common stock     $ 45,000,000    
Number of shares issued (in Shares)   221,052,632   118,513,734  
Shares issued price       $ 2,250,000  
Net proceeds       $ 2,201,925  
Shares issued on conversion (in Shares) 231,578,947        
Common Stock [Member] | Purchase Agreement [Member]          
Common Stock [Line Items]          
Sale of common stock     $ 45,000,000    
Common Stock [Member] | Purchase Agreement with an Investor [Member]          
Common Stock [Line Items]          
Sale of common stock         $ 536,950
Number of shares issued (in Shares)         50,463,718
Shares issued price         $ 550,000
Common Stock [Member] | Minimum [Member]          
Common Stock [Line Items]          
Purchase prices, per share decrease (in Dollars per share)       $ 0.0156  
Common Stock [Member] | Maximum [Member]          
Common Stock [Line Items]          
Purchase prices, per share increase (in Dollars per share)       $ 0.02024  
Preferred Stock [Member]          
Common Stock [Line Items]          
Shares issued on conversion (in Shares) 2,200 2,100      
Conversion of stock amount $ 220,000 $ 210,000      
Conversion price (in Dollars per share) $ 0.00095 $ 0.00095      
v3.25.0.1
Stock Incentive Plans (Details) - shares
6 Months Ended
Jul. 01, 2024
Jan. 27, 2022
Dec. 17, 2018
Dec. 31, 2024
2019 Equity Incentive Plan [Member]        
Stock Incentive Plans [Line Items]        
Shares reserved for issuance       14,729,439
Percentage of exercise option     100.00%  
Stock option       285,270,561
2022 Equity Stock Incentive Plan [Member]        
Stock Incentive Plans [Line Items]        
Shares reserved for issuance       504,948,700
Stock option       448,600,000
Percentage of exercise option issuable   15.00%    
Incentive plan 953,548,700      
Stock options outstanding 6,356,991,335      
Equity Option [Member] | 2019 Equity Incentive Plan [Member]        
Stock Incentive Plans [Line Items]        
Shares reserved for issuance     300,000,000  
Equity Incentive [Member] | 2022 Equity Stock Incentive Plan [Member]        
Stock Incentive Plans [Line Items]        
Issuance pursuant to the plan   400,000,000    
v3.25.0.1
Stock Options and Warrants (Details) - USD ($)
6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Stock Options and Warrants [Line Items]    
Stock compensation expense $ 183,497 $ 144,963
Unrecognized compensation cost $ 3,500,000  
Remaining weighted-average vesting period 1 year 4 months 28 days  
v3.25.0.1
Stock Options and Warrants - Schedule of Stock Option Transactions (Details)
6 Months Ended
Dec. 31, 2024
$ / shares
shares
Schedule of Stock Option [Abstract]  
Number of Options, Outstanding Beginning (in Shares) | shares 266,894,499
Weighted Average Exercise Price, Outstanding Beginning $ 0.011
Weighted Average Grant-Date Per Share Fair Value, Outstanding Beginning $ 0.011
Number of Options, Granted (in Shares) | shares 275,000,000
Weighted Average Exercise Price, Granted $ 0.017
Weighted Average Grant-Date Per Share Fair Value, Granted $ 0.013
Number of Options, Canceled/Expired (in Shares) | shares (6,928,588)
Weighted Average Exercise Price, Canceled/Expired $ 0.01
Weighted Average Grant-Date Per Share Fair Value, Canceled/Expired $ 0.01
Number of Options, Exercised (in Shares) | shares
Weighted Average Exercise Price, Exercised
Number of Options, Outstanding Ending (in Shares) | shares 534,965,911
Weighted Average Exercise Price, Outstanding Ending $ 0.0139
Weighted Average Grant-Date Per Share Fair Value, Outstanding Ending $ 0.012
v3.25.0.1
Stock Options and Warrants - Schedule of Options Outstanding (Details)
6 Months Ended
Dec. 31, 2024
$ / shares
shares
Schedule of Stock Option [Abstract]  
Options Exercisable (in Shares) | shares 255,465,911
Weighted Average Exercise Price of Options Exercisable (in Dollars per share) | $ / shares $ 0.011
Weighted Average Contractual Life of Options Exercisable (Years) 2 years 1 month 24 days
Weighted Average Contractual Life of Options Outstanding (Years) 4 years 10 months 6 days
v3.25.0.1
Stock Options and Warrants - Schedule of Warrant Transactions (Details) - Warrant [Member]
6 Months Ended
Dec. 31, 2024
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Shares, Warrants outstanding, beginning | shares 78,095,239
Weighted Average Exercise Price, Warrants outstanding, beginning | $ / shares $ 0.121
Number of Shares, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Number of Shares, Canceled/Expired | shares
Weighted Average Exercise Price, Canceled/Expired | $ / shares
Number of Shares, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Shares, Warrants outstanding, ending | shares 78,095,239
Weighted Average Exercise Price, Warrants outstanding, ending | $ / shares $ 0.121
v3.25.0.1
Stock Options and Warrants - Schedule of Warrants Outstanding (Details) - Warrant [Member] - shares
6 Months Ended
Dec. 31, 2024
Jun. 30, 2024
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Warrants Exercisable 78,095,239 78,095,239
Weighted Average Contractual Life of Warrants Outstanding and Exercisable (Years) 1 year 2 months 1 day  
v3.25.0.1
Equity Securities, Related Party (Details)
6 Months Ended
May 24, 2024
USD ($)
shares
May 24, 2024
NOK (kr)
shares
Nov. 11, 2022
USD ($)
shares
Nov. 11, 2022
kr / shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Sep. 30, 2024
Sep. 10, 2024
shares
Related Party Transaction [Line Items]                
Purchased shares (in Shares) | shares     13,443,875          
Aggregate consideration     $ 7,000,000          
Exchange rate     10.4094 10.4094        
Interest rate as shareholder     8.30%          
Subscription amount     $ 3,000,000          
Maturity date     Jun. 01, 2025 Jun. 01, 2025        
Convertible share (in Krone per share) | kr / shares       kr 5.0868        
Interest rate percentage     8.00% 8.00%        
Interest income           $ 114,652    
Agreed to receive shares (in Shares) | shares 15,884,744 15,884,744            
Unpaid interest amount $ 3,000,000              
Contributed capital gain 3,139,302              
Conversion of convertible bond 85,815              
Interest received $ 53,487              
Total shares (in Shares) | shares               29,328,619
Fair value shares         $ 0      
TECO Bonds [Member]                
Related Party Transaction [Line Items]                
Principal amount (in Krone) | kr   kr 31,228,200            
Accrued and unpaid interest (in Krone) | kr   541,289            
Total shares (in Shares) | shares               15,884,744
TECO Bonds [Member] | Investor [Member]                
Related Party Transaction [Line Items]                
Accrued and unpaid interest (in Krone) | kr   kr 31,769,489            
TECO [Member]                
Related Party Transaction [Line Items]                
Outstanding shares percentage         13.32%   13.29%  
v3.25.0.1
Equity Securities, Related Party - Schedule of Summarizes our Equity Investments in TECO (Details) - TECO [Member] - USD ($)
6 Months Ended
Dec. 31, 2024
Jun. 30, 2024
Schedule of Summarizes Equity Investments [Line Items]    
Number of Shares (in Shares) 29,328,619  
Cost Basis $ 10,139,302  
Fair Value $ 4,101,402
Unrealized Loss $ (4,101,402)  
November 24, 2022 [Member]    
Schedule of Summarizes Equity Investments [Line Items]    
Number of Shares (in Shares) 13,443,875  
Cost Basis $ 7,000,000  
Fair Value 1,880,032
Unrealized Loss $ (1,880,032)  
May 24, 2024 [Member]    
Schedule of Summarizes Equity Investments [Line Items]    
Number of Shares (in Shares) 15,884,744  
Cost Basis $ 3,139,302  
Fair Value $ 2,221,370
Unrealized Loss $ (2,221,370)  
v3.25.0.1
Investment Income - Schedule of Investment Income (Details) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Net Investment Income [Line Items]        
Total investment income $ 439,645 $ 484,984 $ 919,368 $ 960,593
Interest Earned on Cash [Member]        
Net Investment Income [Line Items]        
Total investment income     675,207 52,468
Interest Earned on Treasury Bills [Member]        
Net Investment Income [Line Items]        
Total investment income     240,475 664,157
Interest Earned on Certificates of Deposit [Member]        
Net Investment Income [Line Items]        
Total investment income     61,200
Interest Earned on Corporate Bonds [Member]        
Net Investment Income [Line Items]        
Total investment income     54,375
Interest Earned on TECO bond [Member]        
Net Investment Income [Line Items]        
Total investment income     114,652
Dividends and Other [Member]        
Net Investment Income [Line Items]        
Total investment income     $ 3,686 $ 13,741
v3.25.0.1
Short Term Investments (Details) - USD ($)
6 Months Ended
Dec. 31, 2023
Sep. 12, 2023
Nov. 11, 2022
Short Term Investments [Line Items]      
Certificate of deposit   $ 5,000,000  
Mature date     Jun. 01, 2025
Certificates of Deposit [Member]      
Short Term Investments [Line Items]      
Mature date   Mar. 12, 2024  
Interest income $ 61,200    
v3.25.0.1
Commitments and Contingencies (Details) - USD ($)
6 Months Ended
Dec. 31, 2024
Oct. 01, 2024
Dec. 31, 2024
Apr. 01, 2024
Commitments and Contingencies [Line Items]        
Rental amount       $ 6,400
University of Iowa [Member]        
Commitments and Contingencies [Line Items]        
Consideration amount   $ 302,459    
Equal installments amount   75,615    
Due per agreement $ 75,615      
University of Michigan [Member]        
Commitments and Contingencies [Line Items]        
Consideration amount   $ 252,246    
Balance due per agreement     $ 63,062  
Prior amended research amount     40,091  
Research agreement balance due per agreement     $ 103,153  
v3.25.0.1
Related Party (Details) - USD ($)
6 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
Related Party [Line Items]        
Accrued expenses $ 161,497     $ 140,558
Accrued salary interest rate     5.00%  
Loan [Member]        
Related Party [Line Items]        
Repaid monthly payment     $ 9,290  
Principal balance 0     $ 45,829
Interest paid $ 620 $ 3,405    
CEO [Member] | Related Party [Member]        
Related Party [Line Items]        
Accrued expenses     $ 211,750  

SunHydrogen (QB) (USOTC:HYSR)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse SunHydrogen (QB)
SunHydrogen (QB) (USOTC:HYSR)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse SunHydrogen (QB)